Mutants of 2019-nCoVs proteins and genetically engineered mRNA and vaccine compositions thereof

By mutating the extracellular domain of the 2019-nCoV S protein and constructing a stable conformational trimer, an mRNA vaccine was prepared, solving the problems of long development cycles and safety risks associated with traditional vaccines and achieving a highly efficient immune response.

CN115960180BActive Publication Date: 2026-11-10BEIJING TRICISIONBIO THERAPEUTICS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202210623377.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-10-09
Filing Date
2022-06-01
Publication Date
2026-11-10
Estimated Expiration
2042-06-01

AI Technical Summary

Technical Problem

Existing traditional vaccines have long development cycles, complex production processes, and potential safety risks. mRNA vaccines have advantages in terms of safety, rapid preparation, and immunogenicity, but the stability of the S protein and the effectiveness of the immune response need to be optimized.

Method used

By mutating amino acid residues in the extracellular domain of the 2019-nCoV S protein, a stable conformational trimer S protein mutant was constructed and encoded with the corresponding mRNA. This mutant was then combined with the domain that helps form the trimer to prepare an mRNA vaccine.

Benefits of technology

It improves the stability of the S protein mutant, enhances the immune response, and can effectively prevent and/or treat diseases related to 2019-nCoV infection, avoiding the safety risks of traditional vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115960180B_ABST
    Figure CN115960180B_ABST
Patent Text Reader

Abstract

This invention involves mutating multiple amino acid residues to proline in the C-terminal amino acid domain of the extracellular domain of the 2019-nCoV spike protein (S protein), providing an S protein mutant with a stable conformational trimer. The invention also includes the construction of mRNA encoding the aforementioned S protein mutant and a vector capable of in vitro transcription to prepare the mRNA. These S protein mutants, and their encoding mRNAs (including further optimized mRNAs), can be used to induce an immune response against 2019-nCoV in subjects, thereby preventing and / or treating diseases or conditions associated with 2019-nCoV infection.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to an earlier application filed on October 9, 2021, with patent application number 202111176258.3, entitled "Mutant of 2019-nCoV S protein and its genetically engineered mRNA and vaccine composition", which is incorporated herein by reference in its entirety. Technical Field

[0002] This invention belongs to the field of biomedicine and vaccine technology, and particularly relates to recombinant antigens for preparing vaccines against 2019-nCoV, their genetically engineered mRNAs and vectors, and their mRNA vaccine compositions. Background Technology

[0003] Coronaviruses are enveloped, positive-sense RNA viruses, a large and diverse family that infects only vertebrates, causing respiratory, digestive, and nervous system diseases in humans and animals. The novel coronavirus (2019-nCoV, also known as SARS-CoV-2) is spherical or ellipsoidal in shape, with a diameter of 80-120 nm. Under an electron microscope, the virus particle surface has ball-and-stick-shaped protrusions composed of the trimeric spike glycoprotein (S). The viral envelope is composed of membrane glycoprotein (M), embedded within the viral envelope through three transmembrane domains. In addition, a small amount of small transmembrane protein—the envelope (E) protein—is also present in the envelope. Finally, the nucleocapsid (N) protein is attached to the RNA genome in a beaded manner, forming a helical symmetrical nucleocapsid. Research results show that S, M, E, and N proteins are the main components of the immune response induced by coronaviruses. In addition, the receptor-binding domain (RBD) in the S protein infects human respiratory epithelial cells by interacting with human ACE2 protein.

[0004] mRNA vaccines offer disruptive advantages in terms of safety, rapid preparation, and immunogenicity. Traditional inactivated, live attenuated, and peptide vaccines involve long development cycles and complex manufacturing processes. However, based on advancements in mRNA modification and delivery tools, once the viral antigen sequence is obtained, clinically scalable mRNA vaccines can be rapidly designed and manufactured within weeks, enabling standardized production and making them highly attractive in responding to pandemic outbreaks. Furthermore, mRNA vaccines do not carry the potential reversal risk of live attenuated vaccines or the reversion mutation problem of inactivated vaccines. In terms of immunogenicity, mRNA vaccines can induce B-cell and T-cell immune responses, generate immune memory, deliver more effective antigens, and express multiple antigens simultaneously. Moreover, mRNA only needs to cross the cell membrane to efficiently express antigen proteins in the cytoplasm; there is no risk of mRNA integrating into the genome. Finally, mRNA is easily degraded after translation into protein, and its transient expression characteristic not only ensures the safety of mRNA drugs but also allows for dosage control, avoiding antigen tolerance (a state of unresponsiveness to specific antigens) caused by long-term exposure to vaccine drugs. Furthermore, since animal-derived viruses are not required in the vaccine development process, the risks associated with the use of viruses and animals are avoided.

[0005] mRNA is transcribed from a DNA template strand, and its sequence is identical to the coding strand and complementary to the template strand. Unlike prokaryotes, in eukaryotes, the mRNA carrying genetic information consists of protein-coding exons and non-coding introns arranged in intervals. Only properly modified and spliced ​​mature mRNA can serve as a template for transport to the cytoplasm for further translation into proteins. Summary of the Invention

[0006] This invention involves mutating multiple amino acid residues to proline at the C-terminal amino acid domain of the extracellular domain of the 2019-nCoV spike protein (S protein), providing an S protein mutant with a stable conformational trimer. An mRNA encoding the aforementioned S protein mutant was constructed, along with a vector capable of in vitro transcription to prepare the mRNA. These S protein mutants, and their encoding mRNAs (including further optimized mRNAs), can be used to induce an immune response against 2019-nCoV in subjects, thereby preventing and / or treating diseases or conditions associated with 2019-nCoV infection. The main structures of the 2019-nCoV viral particle are currently known to include single-stranded positive-sense nucleic acid (ssRNA), spike protein (S), membrane protein (M), envelope protein (E), and nucleocapsid protein (N). Figure 1As shown, the S protein can be divided into the receptor-binding subunit S1 and the membrane fusion subunit S2. The adsorption and invasion of cells by the 2019-nCoV virus mainly depends on the S protein. In this process, the S protein assembles in the form of a homotrimer, and its cytoplasmic tail and transmembrane domain anchor the S protein to the viral membrane. Figure 1 As shown, analysis of the prefusion structure of the S protein revealed that the RBD of the S1 subunit undergoes hinge-like conformational shifts to conceal or expose key receptor-binding sites. The "down" direction represents a receptor-unbinding state, while the "up" direction represents a receptor-binding state, indicating a relatively unstable state. This conformation allows the S protein to readily bind to the host receptor angiotensin-converting enzyme 2 (ACE2). After the RBD binds to the receptor, the S2 subunit changes to the post-fusion conformation by inserting its FP into the host cell membrane. HR1 and HR2 form an antiparallel six-helix bundle (6HB), collectively constituting a fusion core, ultimately leading to the fusion of the viral membrane and the cell membrane. Cryo-electron microscopy experiments identified numerous trimeric S protein domains in the prefusion conformation. The prefusion S protein contains a large number of neutralizing antibody-sensitive epitopes, while the post-fusion conformation minimizes the exposure of these neutralizing-sensitive epitopes, which are only present in the prefusion conformation.

[0007] Therefore, if it is to be used as an antigen in a vaccine, the optimized S protein mutant should be able to retain the epitope present in the prefusion conformation of the S protein and induce antibodies that can inhibit viral fusion.

[0008] The first aspect of the present invention is to provide an S protein mutant.

[0009] S protein mutants are generated by amino acid mutations in the parental S protein, where the mutation can be an amino acid substitution, deletion, and / or insertion. The parental S protein can be the S protein of the 2019-nCoV wild-type strain or the S protein of any mutant strain of 2019-nCoV (the mutation of any mutant strain of 2019-nCoV can occur in the S protein region or in a non-S protein region). In one embodiment of the present invention, the parental S protein is the S protein of the 2019-nCoV B.1.351 mutant strain, which has the following mutations compared to the S protein of the 2019-nCoV wild-type strain: L18F, D80A, D215G, L242_244L del, R246I, K417N, E484K, N501Y, D614G, A701V (the sites are described by their positions in the amino acid sequence shown in SEQ ID NO:1). The parental S protein can be the full-length S protein or a fragment of the full-length S protein (e.g., a truncated sequence of the full-length S protein (e.g., deletion of the cytoplasmic tail and / or transmembrane domain)).

[0010] In this invention, the amino acid positions of the S protein mutant and the parental S protein are described based on the amino acid sequence of the wild-type S protein. The amino acid sequence of the wild-type S protein can be obtained from NCBI GeneID:43740568 and contains 1273 amino acids. Its sequence is shown below and is marked as SEQ ID NO:1 in this invention.

[0011] According to the present invention, the S protein mutant includes at least an extracellular domain, the extracellular domain of which, relative to the extracellular domain of the parental S protein, comprises amino acid mutations at the following positions: F817P, A892P, A899P, A942P, and KV986_987PP, the sites being located and described by the amino acid sequence shown in SEQ ID NO:1. These amino acid mutations can improve the stability of the S protein mutant.

[0012] In some embodiments of the present invention, the S protein mutant has the following mutations relative to the parental S protein: L18F, D80A, D215G, L242_244L del, R246I, K417N, E484K, N501Y, D614G, A701V, the sites being located and described by the amino acid sequence shown in SEQ ID NO:1.

[0013] According to the present invention, in some embodiments, the S protein mutant has a mutation at the furinase cleavage site relative to the parental S protein, specifically by mutating amino acids 682-685 (described by the position of the amino acid sequence shown in SEQ ID NO:1) RRAR to lose its ability to be cleaved by furin-like proteases. In one embodiment of the present invention, RRAR is mutated to GSAS. By mutating the cleavage site in the S protein, the S protein mutant can be prevented from being cleaved by proteases, further improving its stability.

[0014] According to some embodiments of the present invention, the S protein mutant does not contain the transmembrane domain and / or cytoplasmic tail of the S protein.

[0015] According to the present invention, in some embodiments, the S protein mutant may also have an amino acid mutation in the fusion peptide domain relative to the parental S protein. By substituting, deleting, and / or inserting one or more amino acid residues in this region, the fusion peptide domain loses its native function, i.e., its function of mediating viral fusion with the host cell membrane. In some embodiments, the S protein mutant does not contain a fusion peptide domain. By inducing a mutation in the fusion peptide domain in the S protein mutant to render it nonfunctional, the stability of the pre-fusion conformation of the S protein mutant can be improved, thereby preserving and exposing the large number of neutralizing antibody-sensitive epitopes present on the pre-fusion conformation of the S protein.

[0016] In some preferred embodiments of the present invention, the S protein mutant of the present invention is described by the amino acid sequence shown in SEQ ID NO:1, having six proline mutations in the extracellular domain of the S protein: F817P, A892P, A899P, A942P, and KV986_987PP; and the following mutations: L18F, D80A, D215G, L242_244L del, R246I, K417N, E484K, N501Y, D614G, A701V; and a mutation of amino acids 682-685 from RRAR to GSAS; and lacking the transmembrane domain and cytoplasmic tail of the S protein. In one embodiment of the present invention, the S protein mutant comprises the amino acid sequence shown in SEQ ID NO:2.

[0017] According to the present invention, in some embodiments, the S protein mutant is directly fused with a trimer-forming domain at the C-terminus of its extracellular region (amino acids 1-1209, the site being described by the position of the amino acid sequence shown in SEQ ID NO:1). A “trimer-forming domain” refers to a protein or polypeptide domain that, when expressed, can spontaneously or inducedly form a trimer. The trimer-forming domain, when expressed, promotes the formation of a trimer from the recombinant S protein mutant. Various such domains are known in the art. By including a trimer-forming domain in the S protein mutant (e.g., by constructing a fusion protein), it is possible to promote the formation of a trimer conformation of the S protein mutant and / or stabilize the trimer conformation of the S protein mutant. In one embodiment of the present invention, the trimer-forming domain is a T4 Fibritin Foldon Trimerization Motif. In a specific embodiment of the present invention, the amino acid sequence of the T4 Fibritin Foldon Trimerization Motif is shown in SEQ ID NO:3.

[0018] In some preferred embodiments of the present invention, the S protein mutant of the present invention is described by the position of the amino acid sequence shown in SEQ ID NO:1. The mutant has six proline mutations in the extracellular domain of the S protein: F817P, A892P, A899P, A942P, and KV986_987PP; and the following mutations: L18F, D80A, D215G, L242_244L del, R246I, K417N, E484K, N501Y, D614G, A701V; and a mutation of amino acids 682-685 from RRAR to GSAS; and does not contain the transmembrane domain and cytoplasmic tail of the S protein; and directly fuses the T4 FibritinFoldon Trimerization Motif, an auxiliary trimerization domain, to the C-terminus of the extracellular region. In one embodiment of the present invention, the S protein mutant comprises the amino acid sequences of SEQ ID NO:2 and SEQ ID NO:3 directly linked from the N-terminus to the C-terminus. In one embodiment of the present invention, the amino acid sequence of the S protein mutant is the amino acid sequence of SEQ ID NO:2 and the amino acid sequence of SEQ ID NO:3 directly linked from the N-terminus to the C-terminus.

[0019] A second aspect of the present invention is to provide a DNA molecule, an expression vector or cell containing said DNA molecule, said DNA molecule being used to encode the S protein mutant described in the first aspect of the present invention.

[0020] According to the present invention, the DNA molecule may be present in an expression vector, such as a plasmid vector or a viral vector, and transfected into engineered cells for expression to obtain the S protein mutant of the present invention. Alternatively, the DNA molecule may be recombined into the genome of engineered cells and expressed in the engineered cells to obtain the S protein mutant of the present invention.

[0021] In some embodiments of the present invention, the nucleotide sequence of the DNA molecule comprises a nucleotide sequence that is at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homologous to the nucleotide sequence shown in SEQ ID NO:4, wherein the nucleotide sequence shown in SEQ ID NO:4 encodes the amino acid sequence shown in SEQ ID NO:2.

[0022] In some embodiments of the present invention, the nucleotide sequence of the DNA molecule comprises a nucleotide sequence that is at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homologous to the nucleotide sequence shown in SEQ ID NO:5, wherein the nucleotide sequence shown in SEQ ID NO:5 encodes the amino acid sequence shown in SEQ ID NO:3.

[0023] In some embodiments of the present invention, the nucleotide sequence of the DNA molecule comprises a nucleotide sequence directly linked from the 5' end to the 3' end that is at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homologous to the nucleotide sequence of SEQ ID NO:4, and a nucleotide sequence that is at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homologous to the nucleotide sequence of SEQ ID NO:5. In one specific embodiment of the present invention, the nucleotide sequence of the DNA molecule comprises the nucleotide sequence of SEQ ID NO:4 and the nucleotide sequence of SEQ ID NO:5 directly linked from the 5' end to the 3' end.

[0024] An expression vector containing the DNA molecule. According to the present invention, the expression vector may be a prokaryotic cell expression vector or a eukaryotic cell expression vector.

[0025] A cell containing the DNA molecule. According to the invention, the DNA molecule may be present outside the genome of the cell or may be recombined into the genome of the cell.

[0026] A third aspect of the present invention is to provide an mRNA that encodes the S protein mutant described in the first aspect of the present invention.

[0027] According to the present invention, the mRNA contains an open reading frame (ORF) encoding a mutant S protein.

[0028] According to the present invention, the mRNA may include a 5' cap structure, a 5' UTR, an open reading frame (ORF) encoding the S protein mutant, a 3' UTR, and a poly-A tail from the 5' end to the 3' end.

[0029] 5' Cap Structure: A 5' cap is typically a modified nucleotide (especially a guanine nucleotide) added to the 5' end of an mRNA molecule, but atypical cap analogs are also included. Preferably, the 5' cap is added using a 5'-5'-triphosphate bond (also known as m7GpppN). Other examples of 5' cap structures include glycerol groups, reverse deoxygenated debase residues (partially), 4',5'-methylene nucleotides, 1-(β-D-erythrofuranosyl) nucleotides, 4'-thionucleotides, carbocyclic nucleotides, 1,5-dehydrated hexitol nucleotides, L-nucleotides, α-nucleotides, modified base nucleotides, threopentafuranosyl nucleotides, acyclic 3',4'-closed nucleotides, acyclic 3,4-dihydroxybutyl nucleotides, acyclic 3,5-dihydroxypentayl nucleotides, 3'-3'-reverse nucleotide moiety, 3'-3'-reverse debase moiety, 3'-2'-reverse nucleotide moiety, 3'-2'-reverse debase moiety, 1,4-butanediol phosphate, 3'-aminophosphate, hexyl phosphate, aminohexyl phosphate, 3'-phosphate, 3'-thiophosphate, dithiophosphate, or bridged or non-bridged methylphosphonate moiety. These modified 5' cap structures can be used in the context of this invention to modify the mRNA sequence of this invention. In some embodiments of this invention, the 5' cap structures are CAP1 (additional methylation of the ribose of the adjacent nucleotide of m7GpppN), CAP2 (additional methylation of the ribose of the second nucleotide downstream of m7GpppN), CAP3 (additional methylation of the ribose of the third nucleotide downstream of m7GpppN), and CAP4 (additional methylation of the ribose of the fourth nucleotide downstream of m7GpppN).

[0030] Cap analogs: Cap analogs are non-polymerizable dinucleotides that have a cap function because they facilitate translation or localization and / or prevent the degradation of RNA molecules when incorporated at the 5' end. Non-polymerizable means that cap analogs will only be incorporated at the 5' end because they do not have a 5' triphosphate and therefore cannot be extended in the 3' direction by template-dependent RNA polymerase. Cap analogs include, but are not limited to, chemical structures selected from the group consisting of: m7GpppG, m7GpppA, m7GpppC; unmethylated cap analogs (e.g., GpppG); dimethylated cap analogs (e.g., m2,7GpppG), trimethylated cap analogs (e.g., m2,2,7GpppG), dimethylated symmetrical cap analogs (e.g., m7Gpppm7G) or anti-reverse cap analogs (e.g., ARCA; m7,2'OmeGpppG, m7,2'dGpppG, m7,3'OmeGpppG, m7,3'dGpppG and their tetraphosphate derivatives) (Stepinski et al., 2001. RNA 7(10):1486-95).

[0031] The 5' cap structure can be formed using cap analogs in chemical RNA synthesis or in vitro RNA transcription (co-transcriptional capping), or in vitro using capping enzymes (e.g., commercially available capping kits).

[0032] In one embodiment of the present invention, the 5' cap structure is a Cap1 structure.

[0033] According to the present invention, the 5'UTR may comprise the 5'UTR of β-globin or α-globin, or its homologs or fragments. In some embodiments of the present invention, the 5'UTR comprises the 5'UTR of β-globin, or its homologs or fragments. In some embodiments of the present invention, the 5'UTR comprises a nucleotide sequence that is at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homologous to the 5'UTR nucleotide sequence of β-globin shown in SEQ ID NO:6. In one specific embodiment of the present invention, the 5'UTR comprises the 5'UTR nucleotide sequence of β-globin shown in SEQ ID NO:6.

[0034] In some embodiments of the present invention, the 5'UTR further comprises a Kozak sequence. In one embodiment of the present invention, the Kozak sequence is GCCACC.

[0035] According to the present invention, the 3'UTR may comprise the 3'UTR of β-globin or α-globin or its homologs, fragments, or combinations of fragments. In some embodiments of the present invention, the 3'UTR comprises a nucleotide sequence that is at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homologous to the fragment of the α2-globin 3'UTR shown in SEQ ID NO:7. In other embodiments of the present invention, the 3'UTR comprises two end-to-end nucleotide sequences that are at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homologous to the fragment of the α2-globin 3'UTR shown in SEQ ID NO:7. In one specific embodiment of the present invention, the 3'UTR comprises two end-to-end nucleotide sequences shown in SEQ ID NO:7.

[0036] According to the present invention, the length of the poly-A tail can be 50-200 nucleotides, preferably 100-150 nucleotides, for example 110-120 nucleotides, for example about 110 nucleotides, about 120 nucleotides, about 130 nucleotides, about 140 nucleotides, or about 150 nucleotides.

[0037] In one embodiment of the present invention, the nucleotide sequence of the open reading frame (ORF) of the S protein mutant is a nucleotide sequence that is at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homologous to the nucleotide sequence shown in SEQ ID NO:8. The amino acid sequence of the S protein mutant translated from the ORF consists of the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:3 directly linked from the N-terminus to the C-terminus. In a specific embodiment of the present invention, the nucleotide sequence of the open reading frame (ORF) of the S protein mutant is as shown in SEQ ID NO:8.

[0038] In one embodiment of the invention, the mRNA comprises a nucleotide sequence that is at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homologous to the nucleotide sequence shown in SEQ ID NO:9. In a specific embodiment of the invention, the mRNA comprises the nucleotide sequence shown in SEQ ID NO:9.

[0039] According to the present invention, one or more nucleotides in the mRNA may be modified. For example, one or more nucleotides (e.g., all nucleotides) in the mRNA may be independently replaced with naturally occurring or artificially synthesized nucleotide analogs, such as those selected from pseudouridine, 2-thiouridine, 5-methyluridine, 5-methylcytidine, N6-methyladenosine, N1-methylpseudouridine, 5-ethynyluridine, pseudo-UTP, N1-methyl-pseudo-UTP, 5-ethynyl-UTP, 5-methyl-CTP, etc.

[0040] A fourth aspect of the present invention is to provide a nucleic acid molecule encoding the mRNA described in the third aspect of the present invention. The nucleic acid molecule may be, for example, in the form of a vector such as a plasmid vector or a viral vector. In some embodiments, the nucleic acid molecule may be used to prepare the mRNA of the present invention in vitro by transcription.

[0041] In one embodiment of the invention, the nucleic acid molecule is an in vitro transcription vector comprising operatively linked nucleotide sequences encoding a 5'UTR, a 3'UTR, and a poly-A tail. The 5'UTR comprises nucleotide sequences with at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homology to the 5'UTR nucleotide sequence of β-globin shown in SEQ ID NO:6. The 3'UTR comprises two end-to-end nucleotide sequences with at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homology to the 3'UTR of α2-globin shown in SEQ ID NO:7. The length of the poly-A tail can be 50-200 nucleotides, preferably 100-150 nucleotides, such as 110-120 nucleotides, such as about 110 nucleotides, about 120 nucleotides, about 130 nucleotides, about 140 nucleotides, or about 150 nucleotides.

[0042] According to the present invention, the in vitro transcription vector further comprises a nucleotide sequence encoding an open reading frame (ORF) of an S protein mutant. The nucleotide sequence of the open reading frame (ORF) of the S protein mutant is a nucleotide sequence that is at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or about 100% homologous to the nucleotide sequence shown in SEQ ID NO:8.

[0043] In one specific embodiment of the present invention, the in vitro transcription vector comprises operatively linked nucleotide sequences encoding a 5'UTR, an ORF of the S protein mutant, a 3'UTR, and a poly-A tail; the 5'UTR comprises the 5'UTR nucleotide sequence of β-globin as shown in SEQ ID NO:6; the 3'UTR comprises two end-to-end nucleotide sequences as shown in SEQ ID NO:7; the poly-A tail is 50-200 nucleotides in length; and the nucleotide sequence of the open reading frame (ORF) of the S protein mutant is shown in SEQ ID NO:8.

[0044] According to the present invention, commonly used plasmids can be used as vectors. In some embodiments of the present invention, the plasmid is psp73 or pUC57-kana.

[0045] The mRNA of this invention can be prepared using methods known in the art, including but not limited to chemical synthesis or in vitro transcription. In some embodiments of this invention, a nucleic acid molecule encoding mRNA can be artificially synthesized, cloned into a vector, and a plasmid for in vitro transcription can be constructed. The constructed plasmid is transformed into a host bacterium for culture and amplification, and the plasmid is extracted. The extracted plasmid is digested into a linear molecule using a restriction endonuclease immediately following the polyA tail. Using the prepared linearized plasmid molecule as a template, mRNA is prepared using in vitro transcription. An in vitro transcription (IVT) system typically includes a transcription buffer, nucleotide triphosphates (NTPs), an RNase inhibitor, and a polymerase. NTPs can be selected from, but are not limited to, natural and non-natural (modified) NTPs. The polymerase can be selected from, but is not limited to, T7 RNA polymerase, T3 RNA polymerase, and mutant polymerase. A cap structure analog can be added during in vitro transcription to directly obtain mRNA with a cap structure; alternatively, a capping enzyme and dimethyltransferase can be used to add a cap structure to the mRNA after in vitro transcription. The obtained mRNA can be purified using conventional methods in the field, such as chemical precipitation, magnetic beading, affinity chromatography, etc.

[0046] The S protein mutant of the first aspect of the present invention can be directly used as an antigen to prepare vaccines.

[0047] The mRNA described in the third aspect of this invention can be prepared together with lipid compounds into liposomes or lipid nanoparticles encapsulating the mRNA, and then prepared into a vaccine.

[0048] Therefore, a fifth aspect of the present invention is to provide a vaccine composition comprising the S protein mutant described in the first aspect of the present invention, or comprising the mRNA described in the third aspect of the present invention.

[0049] According to the present invention, in addition to containing an S protein mutant or mRNA, a lipid compound for forming liposomes or lipid nanoparticles, the vaccine or vaccine composition may also contain pharmaceutically acceptable excipients and / or immune adjuvants.

[0050] According to the present invention, in the vaccine or vaccine composition, when lipid nanoparticles are used as carriers, mRNA is located in the lipid nanoparticles, and the lipid nanoparticles contain 30-60 mol% of ionizable cationic lipid molecules of formula C, 5-30 mol% of neutral lipid molecules, 30-50 mol% of cholesterol lipid molecules, and 0.4-10 mol% of PEGylated lipid molecules, accounting for 30-60 mol% of their total lipid molecules; preferably, they contain 32-55 mol% of ionizable cationic lipid molecules of formula C, 8-20 mol% of neutral lipid molecules, 35-50 mol% of cholesterol lipid molecules, and 0.5-5 mol% of PEGylated lipid molecules; more preferably, they contain 34-46 mol% of ionizable cationic lipid molecules of formula C, 9-16 mol% of neutral lipid molecules, 37-49 mol% of cholesterol lipid molecules, and 1.3-2.7 mol% of PEGylated lipid molecules.

[0051] Formula C Each n3 is independent of each other and may be the same or different, each n3 being selected from an integer from 1 to 8; each m3 is independent of each other and may be the same or different, each m3 being selected from an integer from 0 to 8; preferably, each n3 is selected from an integer from 4 to 8, and each m3 is selected from an integer from 4 to 8; preferably, each n3 is the same as each other, and each m3 is the same as each other. The compound of formula C is preferably the compound shown below.

[0052]

[0053]

[0054]

[0055]

[0056]

[0057] Neutral lipid molecules are selected from phosphatidylcholine compounds represented by formula E. E, Phosphatidylethanolamine compounds represented by formula F F, wherein Ra, Rb, Rc, and Rd are independently selected from straight-chain or branched C10-30 alkyl groups, straight-chain or branched C10-30 alkenyl groups, preferably CH3(CH2). 17 CH2-, CH3(CH2) 15 CH2-, CH3(CH2) 13 CH2-, CH3(CH2) 11CH2-, CH3(CH2)9CH2-, CH3(CH2)7CH2-, CH3(CH2)7-CH=CH-(CH2)7-, CH3(CH2)4CH=CHCH2CH=CH(CH2)7-, CH3(CH2)7-CH=CH-(CH2)9-.

[0058] Cholesterol lipid molecules are selected from cholesterol, 5-heptadecylresorcinol and cholesterol hemisuccinate.

[0059] PEGylated lipid molecules comprise a lipid moiety and a PEG-based polymer moiety, denoted as "lipid moiety-PEG-number-average molecular weight". The lipid moiety is a diacylglycerol or diacylglycerol amide, selected from dilauroylglycerol, dimyristoylglycerol, dipalmitoylglycerol, distearylglycerol, dilaurylglycerol amide, dimyristoylglycerol amide, dipalmitoylglycerol amide, distearylglycerol amide, 1,2-distearyl-sn-glycerol-3-phosphate ethanolamine, and 1,2-dimyristoyl-sn-glycerol-3-phosphate ethanolamine. Amines; PEGs have a number average molecular weight of about 130 to about 50,000, for example about 150 to about 30,000, about 150 to about 20,000, about 150 to about 15,000, about 150 to about 10,000, about 150 to about 6,000, about 150 to about 5,000, about 150 to about 4,000, about 150 to about 3,000, about 300 to about 3,000, about 1,000 to about 3,000, about 1,500 to about 2,500, for example about 2,000.

[0060] In the vaccine composition, the mass ratio of total lipid molecules to mRNA is 5-20:1.

[0061] The application of the S protein mutant described in the first aspect of the present invention, or the mRNA described in the third aspect of the present invention, in the preparation of vaccines.

[0062] According to the present invention, the vaccine or vaccine composition may be used to prevent and / or treat 2019-nCoV infection or diseases or conditions related to 2019-nCoV infection, wherein the 2019-nCoV may be a wild-type strain or any mutant strain thereof. In one embodiment of the present invention, the 2019-nCoV is a B.1.351 mutant strain.

[0063] The diseases or conditions related to 2019-nCoV infection include, but are not limited to, pneumonia caused by 2019-nCoV infection, headache, nasal congestion, runny nose, cough and / or bronchitis caused by 2019-nCoV infection, disseminated intravascular coagulation caused by 2019-nCoV infection, and sepsis caused by 2019-nCoV infection.

[0064] The sixth aspect of the present invention is to provide the use of the DNA molecule described in the second aspect of the present invention in the preparation of S protein mutants, and the use of the nucleic acid molecule described in the fourth aspect of the present invention in the preparation of the mRNA described in the third aspect of the present invention.

[0065] Sequence list of this invention:

[0066]

[0067]

[0068]

[0069]

[0070]

[0071]

[0072]

[0073] The ionizable lipid compounds of the present invention can be synthesized using methods already available in the art, for example, by reacting an equivalent or more of an amine with an equivalent or more of an epoxy-terminated compound under suitable conditions. The synthesis of the ionizable lipid compounds can be carried out with or without solvent, and the synthesis can be carried out at a higher temperature in the range of 25-100°C. The ionizable lipid compounds can optionally be purified.

[0074] In some embodiments of the present invention, the ionizable lipid compounds of the present invention can be prepared using the following general preparation method.

[0075]

[0076] Step 1: Restore

[0077] In the presence of a reducing agent, the carboxyl group of compound A1 is reduced to a hydroxyl group to obtain compound A2. Examples of reducing agents include, but are not limited to, lithium aluminum hydride and diisobutylaluminum hydride. Examples of solvents used in the reaction include, but are not limited to, ethers (such as diethyl ether, tetrahydrofuran, and dioxane), halogenated hydrocarbons (such as chloroform, dichloromethane, and dichloroethane), hydrocarbons (such as n-pentane, n-hexane, benzene, and toluene), and mixtures of two or more of these solvents.

[0078] Step 2: Oxidation

[0079] In the presence of an oxidizing agent, the hydroxyl group of compound A2 is oxidized to an aldehyde group to obtain compound A3. Examples of oxidizing agents include, but are not limited to, 2-iodobenzoic acid (IBX), pyridine chlorochromate (PCC), pyridine dichlorochromate (PDC), Des Martin oxidant, manganese dioxide, etc. Examples of solvents used in the reaction include, but are not limited to, halogenated hydrocarbons (such as chloroform, dichloromethane, and dichloroethane), hydrocarbons (such as n-pentane, n-hexane, benzene, and toluene), nitriles (such as acetonitrile), and mixtures of two or more of these solvents.

[0080] Step 3: Halogenation-Reduction

[0081] First, under acidic conditions, the aldehyde α-hydrogen of compound A3 undergoes a halogenation reaction with a halogenating agent to obtain an α-haloaldehyde intermediate. Then, in the presence of a reducing agent, the aldehyde group of the α-haloaldehyde is reduced to a hydroxyl group to obtain compound A4. Examples of acidic conditions include, but are not limited to, DL-proline. Examples of halogenating agents include, but are not limited to, N-chlorosuccinimide (NCS) and N-bromosuccinimide (NBS). Examples of reducing agents include, but are not limited to, sodium borohydride, sodium cyanoborohydride, and sodium triacetoxyborohydride.

[0082] Step 4: Epoxidation

[0083] Compound A4 is subjected to an intramolecular nucleophilic substitution reaction in the presence of a base to obtain epoxide compound A5. Examples of bases include, but are not limited to, alkali metal hydroxides or hydrides, such as sodium hydroxide, potassium hydroxide, and sodium hydride. Examples of solvents used in the reaction include, but are not limited to, mixtures of dioxane and water.

[0084] Step 5: Ring-opening reaction

[0085] Compound A5 is reacted with an amine (e.g., N,N-di(2-aminoethyl)methylamine) via a ring-opening reaction to obtain the final compound. Examples of solvents used in the reaction include, but are not limited to, ethanol, methanol, isopropanol, tetrahydrofuran, chloroform, hexane, toluene, and diethyl ether.

[0086] The raw material A1 used in the preparation method can be commercially available or synthesized using conventional methods.

[0087] Lipid nanoparticles can be prepared using methods known in the art. For example, lipid molecules are dissolved in an organic solvent in a molar ratio to prepare a solution of mixed lipids. The solution of mixed lipids is used as the organic phase, and an aqueous solution of the delivered substance (e.g., nucleic acid) is used as the aqueous phase. The organic and aqueous phases are mixed to prepare lipid nanoparticles. Lipid nanoparticles can be prepared using methods including, but not limited to, spray drying, single and double emulsion solvent evaporation, solvent extraction, phase separation, nanoprecipitation, microfluidics, simple and complex coagulation, and other methods well known to those skilled in the art. The preparation method may further include the steps of separating and purifying the lipid nanoparticles. The preparation method may further include the step of lyophilizing the lipid nanoparticles.

[0088] Terminology Explanation:

[0089] In this invention, the novel coronavirus, 2019-nCoV, and SARS-CoV-2 have the same meaning.

[0090] "And / or" will be considered as a specific disclosure of each of the two specified features or components having or not having the other. Therefore, the term "and / or" as used in phrases such as "A and / or B" is intended to include "A and B", "A or B", "A" (alone), and "B" (alone). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to cover each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0091] "Comprising" and "including" have the same meaning and are intended to be open and allow, but do not require, the inclusion of additional elements or steps. When the terms "comprising" or "including" are used herein, the terms "consisting of" and / or "substantially consisting of" are also included and disclosed.

[0092] In this specification and claims, nucleotides are referred to by their generally accepted single-letter codes. Unless otherwise stated, nucleotide sequences are written from left to right in a 5' to 3' orientation. Nucleotides are represented herein by generally known single-letter symbols recommended by the IUPAC-IUB Committee on Biochemical Nomenclature. Thus, A represents adenine, C represents cytosine, G represents guanine, T represents thymine, and U represents uracil. Those skilled in the art will understand that the T base in the codons disclosed herein exists in DNA, while the T base is replaced by a U base in the corresponding RNA. For example, the codon-nucleotide sequences in DNA form disclosed herein, such as vectors or in vitro translation (IVT) templates, have their T bases transcribed as U bases in their corresponding transcribed mRNAs. In this respect, codon-optimized DNA sequences (containing T) and their corresponding mRNA sequences (containing U) are both considered codon-optimized nucleotide sequences of this disclosure. Those skilled in the art will also understand that equivalent codon maps can be produced by replacing one or more bases with non-natural bases.

[0093] The terms "nucleic acid sequence," "nucleotide sequence," or "polynucleotide sequence" are used interchangeably and refer to a continuous nucleic acid sequence. The sequence can be single-stranded or double-stranded DNA or RNA, such as mRNA.

[0094] "A nucleotide sequence encoding..." refers to a nucleic acid (e.g., mRNA or DNA molecule) coding sequence that encodes a polypeptide. The coding sequence may further include start and stop signals operatively linked to regulatory elements, including promoters and polyadenylation signals capable of directing expression in the cells of an individual or mammal administering the nucleic acid.

[0095] In this specification and claims, conventional single-letter or three-letter codes for amino acid residues are used. Unless otherwise stated, amino acid sequences are written from left to right with the amino-to-carboxyl orientation.

[0096] “Approximately”: The term “approximately” used in conjunction with numerical values ​​throughout the specification and claims indicates a range of accuracy familiar and acceptable to those skilled in the art. Typically, this range of accuracy is ±10%.

[0097] For ease of reference, the S protein mutants of this invention are described using the following naming rules: original amino acid: position: substituted amino acid. According to these rules, for example, asparagine at position 30 being replaced by alanine is represented as: Asn30Ala or N30A; the absence of asparagine at the same position is represented as: Asn30* or N30*; the insertion of another amino acid residue, such as lysine, is represented as: Asn30AsnLys or N30NK; the absence of a continuous sequence of amino acid residues, such as the absence of amino acid residues 242-244, is represented as (242-244)* or Δ(242-244) or 242_244del; if, compared to other S protein parents, the S protein mutant contains a "deletion" and an insertion at that position, it is represented as: *36Asp or *36D, indicating a deletion at position 36 and the insertion of asparagine. When one or more optional amino acid residues can be inserted at a given position, it is represented as: N30A,E, or N30A or N30E. Furthermore, when this document identifies a suitable position for modification without suggesting any specific modification, it should be understood that any amino acid residue can substitute for the amino acid residue at that position. Therefore, for example, when modification of asparagine at position 30 is mentioned but not specified, it should be understood that the asparagine can be omitted or substituted with any other amino acid, i.e., any one of R, D, A, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, V. In addition, "N30X" refers to any of the following substitutions: N30R, N30D, N30C, N30Q, N30E, N30G, N30H, N30I, N30L, N30K, N30M, N30F, N30P, N30S, N30T, N30W, N30Y, or N30V; or abbreviated as: N30R,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V.

[0098] Homology: As used herein, the term "homology" refers to the overall correlation between polymer molecules, for example, between nucleic acid molecules (e.g., DNA and / or RNA molecules) and / or between polypeptide molecules. Generally, the term "homology" implies an evolutionary relationship between two molecules. Therefore, two homologous molecules will share a common evolutionary ancestor. In the context of this disclosure, the term homology includes both identity and similarity.

[0099] In some embodiments, polymer molecules are considered “homological” if at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the monomers in the molecule are identical (completely identical monomers) or similar (conservative substitutions). The term “homological” necessarily refers to a comparison between at least two sequences (polynucleotide or polypeptide sequences).

[0100] Identity: As used herein, the term “identity” refers to the overall monomer conservation between polymer molecules, such as between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. For example, the percentage identity of two polynucleotide sequences can be calculated by aligning them for optimal comparison purposes (e.g., vacancies can be introduced in one or both of the first and second nucleic acid sequences for optimal alignment, and dissimilar sequences can be omitted for comparison purposes). In some embodiments, the length of the sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. Nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percentage identity between two sequences is a function of the number of common positions shared by the sequences, taking into account the number of vacancies that need to be introduced to achieve optimal alignment of the two sequences and the length of each vacancy. Sequence comparison and determination of the percentage identity between two sequences can be accomplished using mathematical algorithms. When comparing DNA and RNA, thymine (T) and uracil (U) can be considered equivalent.

[0101] Suitable software programs are available from various sources and can be used for the alignment of both protein and nucleotide sequences. For example, a suitable program for determining percentage sequence identity is Bl2seq, which is part of the BLAST program suite available from the National Center for Biotechnology Information's BLAST website (blast.ncbi.nlm.nih.gov). Bl2seq uses either the BLASTN or BLASTP algorithm to compare two sequences. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs are, for example, Needle, Stretcher, Water, or Matcher, part of the bioinformatics EMBOSS program suite, and are also available from the European Institute of Bioinformatics (EBI) at www.ebi.ac.uk / Tools / psa. Sequence alignment can be performed using methods known in the art, such as MAFFT, Clustal (ClustalW, Clustal X, or Clustal Omega), MUSCLE, etc.

[0102] The terms "coding region" and "coding area" refer to open reading frames (ORFs) in polynucleotides that, when expressed, produce polypeptides or proteins.

[0103] "Operationally linked" refers to a functional link between two or more molecules, constructs, transcripts, entities, parts, etc.

[0104] Domain: As used herein, when referring to a polypeptide, the term “domain” refers to a motif of a polypeptide that has one or more identifiable structural or functional features or properties (e.g., binding capacity, serving as a site for protein-protein interactions).

[0105] Expression: As used herein, “expression” of a nucleic acid sequence means one or more of the following events: (1) the generation of an mRNA template from a DNA sequence (e.g., by transcription); (2) the processing of the mRNA transcript (e.g., by splicing, editing, 5' cap formation and / or 3' end processing); (3) the translation of mRNA into a polypeptide or protein; and (4) post-translational modifications of the polypeptide or protein.

[0106] The terms "protein mutant" or "peptide mutant" refer to molecules whose amino acid sequence differs from the native or reference sequence. Compared to the native or reference sequence, amino acid sequence mutants may have substitutions, deletions, and / or insertions at certain positions within the amino acid sequence. Typically, mutants will have at least approximately 50% identity with the native or reference sequence, at least approximately 60% identity, at least approximately 70% identity, at least approximately 80% identity, at least approximately 90% identity, at least approximately 95% identity, or at least approximately 99% identity.

[0107] "Alkyl" refers to a saturated hydrocarbon group obtained by removing a single hydrogen atom from a hydrocarbon moiety containing 1 to 30 carbon atoms. Examples of alkyl groups include (but are not limited to) methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, and n-dodecyl.

[0108] "Alkenyl" refers to a monovalent group obtained from a hydrocarbon moiety having at least one carbon-carbon double bond by removing a single hydrogen atom. Alkenyl groups include, for example, vinyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, etc.

[0109] "Pharmaceutically acceptable excipients" means any component other than the S protein mutant or mRNA described herein, and which has substantially non-toxic and non-inflammatory properties in patients, including but not limited to any and all solvents, dispersion media or other liquid carriers, dispersing or suspending agents, diluents, granulators and / or dispersants, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, binders, lubricants, colorants, sweeteners or flavorings, stabilizers, antioxidants, antimicrobial or antifungal agents, molar osmolality adjusters, pH adjusters, buffers, chelating agents, cryoprotectants, and / or fillers, as appropriate for the desired specific dosage form. Various excipients used to formulate pharmaceutical compositions and techniques used to prepare compositions are known in the art. Exemplary antimicrobial or antifungal agents include, but are not limited to, benzalkonium chloride, benzyl chloride, methylparaben, ethylparaben, propylparaben, butylparaben, benzoic acid, hydroxybenzoic acid, potassium or sodium benzoate, potassium or sodium sorbate, sodium propionate, sorbic acid, etc., and combinations thereof. Exemplary preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, ascorbic acid, butylated anisole, ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), etc., and combinations thereof. Exemplary buffers for controlling pH may include, but are not limited to, sodium phosphate, sodium citrate, sodium succinate, histidine (or histidine-HCl), sodium malate, sodium carbonate, etc., and / or combinations thereof. Exemplary cryoprotectants include, but are not limited to, mannitol, sucrose, trehalose, lactose, glycerol, dextrose, etc., and combinations thereof. Exemplary fillers may include, but are not limited to, sucrose, trehalose, mannitol, glycine, lactose, raffinose, and combinations thereof. Attached Figure Description

[0110] Figure 1This diagram illustrates the primary structure of the 2019-nCoV S protein and its conformation before prefusion. Part A of the diagram shows the primary structure of the S protein: SS (signal sequence), NTD (N-terminal domain), RBD (receptor binding domain), S2' (S2' protease cleavage site), FP (fusion peptide), HR1 (heptad repeat 1), CH (central helix), CD (connector domain), HR2 (heptad repeat 2), TM (transmembrane domain), CT (cytoplasmic tail), and the arrows indicate protease cleavage sites. The S1 subunit precedes S1 / S2, and the S2 subunit follows. Part B of the diagram shows the side and top views of the S protein structure before prefusion.

[0111] Figure 2 : A statistical graph showing the intracellular protein expression levels of mRNA prepared from different in vitro transcription vectors using Firefly Luc as a reporter protein.

[0112] Figure 3 The integrity of B.1.351 mRNA was analyzed using an RNA 6000 nano chip on a 2100 bioanalyzer.

[0113] Figure 4 ELISA was used to detect the expression level of the S protein mutant in the supernatant after nucleic acid transfection of CHO-K1 cells.

[0114] Figure 5 : 3D structural diagram of the S protein mutant of this invention.

[0115] Figure 6 This is a statistical graph showing the production of binding antibodies in BALB / c mice after immunization with the S protein mutant of this invention. In the graph, a represents the trimer result of the wild-type S protein, b represents the trimer result of the S protein translated from B.1.351 mRNA, and c represents the blank control.

[0116] Figure 7: A statistical graph showing the production of binding and neutralizing antibodies in BALB / c mice after immunization with lipid nanoparticles encoding the mRNA of the S protein mutant. In the graph, d, e, and f represent the results of binding antibody detection after immunization with lipid nanoparticles (LNPs) containing 5 μg, 1 μg, and 0.2 μg mRNA, respectively, with the vertical axis representing concentration (μg / ml). In the graph, g, h, and i represent the results of neutralizing antibody detection after immunization with lipid nanoparticles (LNPs) containing 5 μg, 1 μg, and 0.2 μg mRNA, respectively, with the horizontal axis representing the logarithmic conversion value of serum dilution and the vertical axis representing the inhibition rate (%).

[0117] Figure 8 The expression level of S protein in the supernatant after cell transfection with the mRNA of the present invention was encapsulated by lipid nanoparticles prepared from II-37 and MC3.

[0118] Figure 9 Schematic diagram of the immunization strategy for the immunogenicity test of mRNA vaccine in BALB / c mice.

[0119] Figure 10 Results of detection of SARS-CoV-2B.1.351-specific IgG binding antibody in BALB / c mice after mRNA vaccine immunization. BALB / c mice (n=4) were intramuscularly injected with different doses of mRNA vaccine or phosphate-buffered saline (PBS, control group, n=4) on days 0 and 21. Blood samples were collected on day 28, and the concentration of SARS-CoV-2B.1.351-specific IgG binding antibody in the blood samples was determined by enzyme-linked immunosorbent assay (ELISA). Horizontal lines represent medians; each point represents a single animal, and points with the same value are covered. The numbers shown in the figure are median values. P-values ​​were analyzed using one-way ANOVA (ns, p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001).

[0120] Figure 11 Results of competitive inhibition of ACE2 in BALB / c mice after mRNA vaccination. Blood samples were collected on day 28, and the titer of neutralizing antibodies that competitively bind to B.1.351 protein with angiotensin-converting enzyme 2 (ACE2) was measured. Results are expressed as inhibition rate. The numbers shown in the figure are median values, and 20% is the lower limit of detection.

[0121] Figure 12Neutralizing antibody levels in the blood of BALB / c mice after immunization with mRNA vaccine. BALB / c mice (n=4) were intramuscularly injected with different doses of mRNA vaccine or phosphate-buffered saline (PBS, control group, n=4) on days 0 and 21. Blood samples were collected on day 42, and the 50% neutralizing titer (pVNT50) of the VSV-SARS-CoV-2 B.1.351 pseudovirus was determined by the reporter gene assay (Vazyme). The figures shown in the figure are median values.

[0122] Figure 13 Neutralizing antibody levels in the blood of BALB / c mice after immunization with mRNA vaccine. BALB / c mice (n=4) were intramuscularly injected with different doses of mRNA vaccine or phosphate-buffered saline (PBS, control group, n=4) on days 0 and 21. Blood samples were collected on day 42, and the titers of neutralizing antibodies against the B.1.351 live virus strain were measured. The numbers shown in the figure are median values.

[0123] Figure 14 Schematic diagram of the immunization strategy for H11 K18-hACE2 transgenic mice.

[0124] Figure 15 Following immunization of K18-hACE2 mice with mRNA vaccine, specific IgG binding antibody expression was observed. Mice (n=12) were intramuscularly injected with different doses of mRNA vaccine or saline on days 0 and 25 (control group, n=12); the challenge control group (n=8) received no injection. Blood samples were collected on day 32, and the concentration of SARS-CoV-2B.1.351-specific IgG binding antibodies in the blood samples was measured by ELISA. Each point represents a single animal, and points with the same value were covered. The numbers shown in the figure are medians. P-values ​​were analyzed using one-way ANOVA (ns, p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001).

[0125] Figure 16 Results of ACE2 competitive binding inhibition after immunization of K18-hACE2 mice with mRNA vaccine. Blood samples were collected on day 32, and the titer of neutralizing antibodies that competitively bind to B.1.351 protein with ACE2 was measured. Results are expressed as inhibition rate (%). The numbers shown in the figure are median values, and 20% is the inhibition rate cut-off value.

[0126] Figure 17 A diagram illustrating the immunization strategy for rhesus monkeys.

[0127] Figure 18Results of ACE2 competitive inhibition assay in rhesus monkeys immunized with mRNA vaccine. Male rhesus monkeys (8 years old) were intramuscularly injected with 10 μg, 30 μg, or 100 μg of mRNA vaccine on days 0 and 28 (n=5), while the control group was injected with saline (n=5). Blood samples were collected on day 35, and the titer of neutralizing antibodies that competitively bind to B.1.351 protein with ACE2 was measured. Results are expressed as inhibition rate (%). The numbers shown in the figure are median values, and 20% is the inhibition rate cut-off value.

[0128] Figure 19 Inter-batch stability of three pilot-scale mRNA vaccine samples (tri02101-1, tri02101-2, and tri02101-3). Top left figure: Spike protein expression in A549 cells was detected using ELISA for the three batches of formulation. Top right figure: Blood samples were collected from mice immunized with the three batches of mRNA vaccine on day 28 to determine the titer of neutralizing antibodies that competitively bind to B.1.351 protein against ACE2. Results are expressed as inhibition rate (%), with 20% as the cut-off value. Bottom figure: After the mRNA vaccine was stored at -80°C for 2 days and 2 months, it was reconstituted according to standard operating procedures and used to infect A549 cells. Spike protein expression was detected by ELISA 48 hours later. EC50 was analyzed using PRISM software with log (agonist) vs. response-variable slope (four parameters).

[0129] Figure 20 Statistical chart of viral load results in mice challenge experiment with strain B.351. Detailed Implementation

[0130] The technical solution of the present invention will be further described in detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanatory of the present invention, and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are covered within the scope of protection intended by the present invention.

[0131] Unless otherwise stated, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods. The experimental methods described are conventional molecular biology methods in the art and can be performed with reference to molecular biology lab manuals or kit product instructions.

[0132] Example 1: Efficiency Comparison Experiment of the IVT Vector of the Present Invention

[0133] In this embodiment, Firefly Luc was used as a reporter protein. Different IVT vectors were constructed to synthesize mRNA capable of translating Firefly Luc in vitro, and the translation efficiency of synthesized mRNAs with different sequence characteristics was compared.

[0134] Using conventional plasmid vector construction techniques in the field, the coding sequence of Firefly Luc was cloned into the multiple cloning site of the corresponding vectors to obtain vectors numbered IVT1, IVT2, IVT3 and IVT4, respectively. Then, the corresponding Firefly Luc mRNA samples were prepared by in vitro transcription using the AM1344 kit according to the aforementioned vectors.

[0135] Vectors IVT1 through IVT4 were all modified from the commercial vector psp73. The following sequences were inserted at the XhoI / NdeI restriction site of vector psp73. IVT1 did not include a UTR sequence, and the polyA tail was 64 alphas long. IVT2 used the 5' UTR shown in SEQ ID NO:6 and the 3' UTR sequence of GCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGC (the 3' UTR sequence of β-globin), with a polyA length of 120 alphas. IVT3 used the 5' UTR shown in SEQ ID NO:6 and the 3' UTR sequence shown in SEQ ID NO:7, with a polyA length of 120 alphas. IVT4 used the 5' UTR shown in SEQ ID NO:6 and two tandem repeats of SEQ ID NO:6. The 3'UTR sequence shown in NO:7 has a polyA length of 120 A's. Multiple cloning sites containing the common restriction enzyme sites HindIII and EcoRI were inserted between the 5'UTR and 3'UTR sequences. The coding sequence of Firefly Luc was then cloned into the HindIII and EcoRI multiple cloning sites. All vectors were constructed by GenScript using gene synthesis methods.

[0136] Each Firefly Luc mRNA sample was transfected into CHO cells using Lipofectamine 2000 (cat #11668030, purchased from Thermo Fisher Scientific) as the transfection reagent, and then transfected using Dual-Lumi. TMA dual-luciferase reporter gene assay kit (at#RG088S, purchased from Shanghai Beyotime Biotechnology Co., Ltd.) was used to detect luciferase. Firefly Luc DNA was transformed into the psicheck2 plasmid as a positive control (psicheck2 plasmid, cat#60908-6151, purchased from Beijing Tianenze Gene Technology Co., Ltd.). The specific steps were as follows: On day one, CHO cells were seeded into 96-well plates at 1.5 × 10⁶ cells per well. 4 Cells were cultured overnight in F12K + 10% FBS. On the second day, before transfection, the medium was changed to serum-free F12K medium, and mRNA or DNA was transfected into CHO cells using Lipofectamine 2000. The amount of nucleic acid used per well was 100 ng, the amount of liposomes used was 0.3 μl, and the total volume of each well was 100 μl. The cells were cultured overnight. On the third day, the serum-free medium was changed to complete medium (F12K + 10% FBS), and the cells were cultured for another 24 hours. On the fourth day (48 hours after transfection), the Firefly Luc fluorescence value was detected.

[0137] The results are as follows Figure 2 As shown in the figure. "DNA" is the positive control (psicheck2 plasmid carrying Firefly Luc DNA), "IVT1-Luc", "IVT2-Luc", "IVT3-Luc", and "IVT4-Luc" represent the corresponding Firefly Luc mRNAs transcribed in vitro from vectors of IVT1, IVT2, IVT3, and IVT4, respectively, and "Nagative control" is the negative control. Figure 2 It is evident that, under the same mRNA transfection level, the protein expression level of IVT4-Luc is much higher than that of the other three mRNAs, by 2-3 times, indicating that IVT4-Luc has good stability and high translation efficiency.

[0138] Example 2: Preparation and Translation of B.1.351 mRNA

[0139] 1. A nucleic acid sequence encoding the mRNA shown in SEQ ID No. 8 is artificially synthesized and cloned after the T7 promoter of the pUC57-kana vector, which has been previously modified to contain sequences encoding SEQ ID NO: 6, the Kozak sequence, two consecutive SEQ ID NO: 7 sequences, and a polyA tail. The nucleic acid sequence encoding the mRNA shown in SEQ ID NO: 8 is cloned at the multiple cloning site between the Kozak sequence and the two consecutive SEQ ID NO: 7 sequences to construct a plasmid for in vitro transcription.

[0140] 2. Transform the constructed plasmid into E. coli Dh5a, culture and amplify, and extract the plasmid.

[0141] 3. The extracted plasmid was digested into linear molecules using the restriction endonuclease SpeI, which is located immediately after the polyA tail.

[0142] 4. Using the prepared linearized plasmid molecule as a template, mRNA was prepared using in vitro transcription (Thermo's In Vitro Transcription Kit A45975). The sequence of the mRNA is shown in SEQ ID NO:9, and will be referred to as B.1.351mRNA below. The S protein mutant obtained after translation from this mRNA is the present invention, whose amino acid sequence from the N-terminus to the C-terminus is a direct link between the amino acid sequences of SEQ ID NO:2 and SEQ ID NO:3. After in vitro transcription, a CAP1 cap structure was added to the mRNA using a capping enzyme and dimethyltransferase.

[0143] 5. Purification of mRNA: The obtained mRNA stock solution was purified using affinity chromatography.

[0144] 6. mRNA quality control: The prepared mRNA was analyzed for integrity using an RNA 6000 nanochip on a 2100 bioanalyzer. The results are as follows: Figure 3 As shown, the transcribed mRNA band was single and showed no obvious degradation.

[0145] In addition, the Spike fragment was excised from the commercially available plasmid pCMV3-spike using the restriction endonucleases HindIII and EcoRI, and inserted between the HindIII and EcoRI sites of the IVT1 vector in Example 1 to obtain the IVT1-spike plasmid. This plasmid was then point-mutated to obtain the IVT1-spike-D614G plasmid. Using this plasmid as a template, spike-D614G mRNA was transcribed in vitro to express the full-length S protein containing the D614G mutation.

[0146] 7.B.1.351 mRNA expression at the cellular level: Using the CHO-K1 cell line as the expression system, mRNA was transfected using Lipofectamine Messenger MAX Reagent (Invitrogen, Cat#1168-027). After culturing for 48 h, the cell culture supernatant was collected, and the expression level of S protein was detected using an enzyme-linked immunosorbent assay (ELISA) kit to assess whether the mRNA could be translated into protein. Results are as follows: Figure 4 As shown. Figure 4In this context, "spike DNA" refers to the commercially available plasmid pCMV3-spike (purchased from Sinocare), which expresses the full-length wild-type S protein; "spike-D614G mRNA" refers to the aforementioned mRNA expressing the full-length S protein containing the D614G mutation; and "spike B.1.351 mRNA" refers to the aforementioned B.1.351 mRNA, which expresses the S protein mutant described in this invention. The results indicate that the mRNA of this invention can highly express the S protein mutant in cells.

[0147] After purification, the obtained S protein mutant was structurally analyzed using cryo-electron microscopy. The 3D structure of the S protein is shown below. Figure 5 As shown, the S protein mutant exhibits a stable prefusion spike structure. The B.1.351 mutant strain differs from the wild-type strain in nine mutation sites, three of which are in the RBD region. Previously reported wild-type prefusion S protein RBD regions primarily exhibit a structure of one open and two closed segments. The S protein mutant of this invention exhibits a flexible structure primarily of two open and one closed segments. This structural difference forms the basis for enhanced viral binding to the ACE2 receptor and increased infectivity. Furthermore, this structural difference leads to significant differences in the immunogenic epitopes of the S protein, resulting in significant differences in antibodies, especially neutralizing antibodies, induced by different structures.

[0148] Example 3. Determination of the immunogenicity of S protein mutants

[0149] The production of binding and neutralizing antibodies induced by the S protein mutant was evaluated using BALB / c mice: 6-week-old female BALB / c mice were immunized initially and then twice, with blood samples collected 14 days after immunization. The expression of binding antibodies against the S protein mutant was detected by ELISA, and the titer of neutralizing antibodies against the S protein mutant was detected by chemiluminescence.

[0150] ELISA method for detecting binding antibodies: The binding antibodies against S protein mutants in the plasma of immunized mice are captured by coating a plate with commercially available S protein, and then the absorbance is detected by biotin-labeled detection antibody. Chemiluminescence assay for neutralizing antibody titers against S protein mutants: After immunization, mouse plasma was neutralized with SPIKE lentivirus carrying the luciferase reporter gene (Zhongji Dangkang; trade name: SRAS-CoV-2 pseudovirus (B.1.351)-LUC; trade number: DZPSC-L-0; batch number: K05202102) and then infecting 293T cells (Zhongji Dangkang; trade name: “YJ1B09”hACE2-293T cell lines; trade number: YJ293T-01; batch number: A23202001) that highly express ACE-2. The neutralizing antibody titers in the plasma were assessed using chemiluminescence (Bright-Lumi II firefly luciferase reporter gene assay kit, brand: Beyotime; trade number: RG052M).

[0151] The control group consisted of 9 mice, each injected subcutaneously with 2 μg of protein. Among them, 3 mice were injected with the purified trimer of the S protein translated from B.1.351 mRNA in Example 2, 3 mice were injected with the trimer of the wild-type S protein, and 3 mice were injected with blank lipid nanoparticles. The lipid nanoparticles were formulated with a molar ratio of II-37:DSPC:CHOL:DMG-PEG2000 of 35:15:48.5:1.5.

[0152] The experimental group consisted of 18 mice, which were subcutaneously injected with lipid nanoparticles containing mRNA. Mice 1-6 were injected with 0.2 μg of lipid nanoparticles containing mRNA (LNP), mice 7-12 were injected with 1 μg of lipid nanoparticles containing mRNA (LNP), and mice 13-18 were injected with 5 μg of lipid nanoparticles containing mRNA (LNP). The mRNA was B.1.351 mRNA from Example 2. The lipid formulation of the lipid nanoparticles was II-37:DSPC:CHOL:DMG-PEG2000 in a molar ratio of 35:15:48.5:1.5.

[0153] The levels of binding antibodies and neutralizing antibodies in mice after primary and secondary immunization are as follows: Figure 6-7 As shown.

[0154] Depend on Figure 6As shown in a, b, and c, the purified S protein trimer translated from B.1.351 mRNA in Example 2 and the wild-type S protein trimer can both induce anti-S protein binding antibodies in mice. A high concentration of binding antibodies was produced during the second immunization in experimental mice. Eight weeks after the second immunization, the concentration of the binding antibodies remained at a high level. It was calculated that the concentration of binding antibodies after the second immunization was about 2.2 μg / ml, and it could still be maintained at about 1.6 μg / ml eight weeks after the second immunization.

[0155] Depend on Figure 7 As shown in d, e, and f, even in the low-dose (0.2 μg) injection group, mice immunized with the LNP-encapsulated mRNA preparation induced the formation of anti-S protein-binding antibodies. The calculated antibody levels were approximately 0.1-0.3 μg / ml. Figure 7 As can be seen from the g, h, and i values, mice immunized with the LNP-encapsulated mRNA preparation after secondary immunization induced good neutralizing antibodies, with GMT values ​​of 78.69, 21.9, and 72.19, respectively.

[0156] Example 4: Synthesis of Ionizable Lipid II-37

[0157]

[0158] Synthesis of linolenic acid (a2): LiAlH4 (7.20 g) and linolenic acid (50 g, a1) were added to 950 mL of tetrahydrofuran at 0 °C. The mixture was then stirred at 25 °C for 2 h. Thin-layer chromatography (TLC) showed that after the reaction was complete, water (7.2 mL), NaOH aqueous solution (7.2 mL, 15% by mass), and water (21.6 mL) were added sequentially to quench the reaction mixture. A suitable amount of Na2SO4 was added and the mixture was stirred for 15 minutes. The mixture was then filtered through a Buchner funnel, and the filter cake was washed with ethyl acetate. The filtrate was collected and concentrated by evaporation to obtain 47.4 g of the target product, linolenic acid (a2).

[0159] 1 H NMR (400MHz, CDCl3): δ5.27-5.44(m,4H),3.63(t,J=6.63Hz,2H),2.77(t,J=6.44H z,2H),1.97-2.12(m,4H),1.57-1.63(m,1H),1.20-1.46(m,18H),0.83-0.95(m,3H)

[0160] Synthesis of (9Z,12Z)-octadec-9,12-dienal (a3): Linoleic acid (25.0 g, a2) and 2-iodobenzoic acid (39.4 g) were added to 170 mL of acetonitrile at room temperature, and the mixture was stirred at 85 °C for 4 h. The reaction solution was filtered through a Buchner funnel and the filter cake was washed with dichloromethane. The filtrate was collected and concentrated by evaporation to give 24.0 g of the target product (9Z,12Z)-octadec-9,12-dienal (a3).

[0161] 1 H NMR (400MHz, CDCl3): δ9.76(t,J=1.76Hz,1H),5.25-5.43(m,4H),2.76(t,J=6.17Hz,2H),2.41(td,J=7 .33,1.87Hz,2H),2.04(q,J=6.84Hz,4H),1.56-1.68(m,2H),1.22-1.36(m,14H),0.88(t,J=6.73Hz,3H)

[0162] Synthesis of (9Z,12Z)-2-chloro-octadec-9,12-dien-1-ol (a4): At 0 °C, (9Z,12Z)-octadec-9,12-dienal (43.0 g, a3), DL-proline (5.62 g), and N-chlorosuccinimide were added to 246 mL of acetonitrile, and the mixture was stirred at 0 °C for 2 h. After the reaction was complete, the reaction mixture was diluted with anhydrous ethanol (246 mL), and sodium borohydride (8.8 g) was added. The mixture was then stirred at 0 °C for 4 h. The reaction mixture was quenched with water (120 mL) and extracted with methyl tert-butyl ether. The combined organic phases were washed with saturated brine, dried over sodium sulfate, filtered, and concentrated by evaporation to obtain the target product (9Z,12Z)-2-chloro-octadec-9,12-dien-1-ol (a4, 46 g), which was used directly in the next step.

[0163] 1 H NMR (400MHz, CDCl3): δ5.25-5.51(m,4H),3.97-4.07(m,1H),3.79(dd,J=12.01,3.63Hz,1H),3.59- 3.70(m,1H),2.67-2.90(m,2H),1.96-2.15(m,5H),1.64-1.82(m,1H),1.20-1.49(m,15H),0.89(br t,J=6.75Hz,3H)

[0164] Synthesis of 2-[(7Z,10Z)-hexadecane-7,10-diene]ethylene oxide (a5): At room temperature, (9Z,12Z)-2-chloro-octadecane-9,12-dien-1-ol (45 g, a4) and an aqueous solution of sodium hydroxide (120 g of sodium hydroxide dissolved in 585 mL of water) were added to 450 mL of 1,4-dioxane. After the addition was complete, the mixture was stirred at 35 °C for 2 h. After the reaction was completed by TLC, the reaction solution was separated by a separatory funnel, washed with saturated brine, dried with sodium sulfate, filtered, and concentrated by evaporation. The residue was then purified by rapid column chromatography with petroleum ether / ethyl acetate to obtain 29.11 g of the target product 2-[(7Z,10Z)-hexadecane-7,10-diene]ethylene oxide (a5).

[0165] 1 H NMR (400MHz, CDCl3): δ5.27-5.46(m,4H),2.87-2.98(m,1H),2.70-2.85(m,3H),2.4 6(dd,J=5.00,2.75Hz,1H),1.94-2.21(m,4H),1.24-1.58(m,17H),0.78-1.00(m,3H)

[0166] Synthesis of II-37: At room temperature, 2-[(7Z,10Z)-hexadecane-7,10-diene]ethylene oxide (5 g) and N,N-bis(2-aminoethyl)methylamine (739 mg) were added to 10 mL of ethanol, and the mixture was stirred at 90 °C for 36 h. The reaction solution was evaporated and concentrated, and the residue was purified by rapid column chromatography with dichloromethane / methanol elution to obtain crude product II-37 (4 g). The target product was further purified by rapid column chromatography with dichloromethane / methanol to obtain II-37 (2.2 g).

[0167] 1 H NMR (400MHz, CDCl3): δ5.27-5.44(m,12H),3.48-3.79(m,3H),2.63-3.00(m,12H),2. 16-2.61(m,12H),2.05(q,J=6.80Hz,12H),1.18-1.57(m,51H),0.89(t,J=6.88Hz,9H)

[0168] ESI-MS: m / z 910.8 [M+H] + 911.8[M+2H] + 912.8 [M+3H] +

[0169] Example 5: Comparison of the effects of II-37 and commercially available ionizable cationic lipid molecule MC3

[0170] MC3 is: 4-(N,N-dimethylamino)butyric acid (6Z,9Z,28Z,31Z)-heptadecane-6,9,28,31-tetraen-19-yl ester.

[0171] Accurately weigh compounds II-37, MC3, DSPC, CHOL, and DMG-PEG2000, and dissolve each lipid in anhydrous ethanol in a suitable container. Prepare lipid nanoparticles using II-37 and MC3 respectively, with the following molar ratios: II-37:DSPC:CHOL:DMG-PEG2000 = 45:15:38.5:1.5; MC3:DSPC:CHOL:DMG-PEG2000 = 45:15:38.5:1.5. Mix the lipid solutions thoroughly according to the ratios to form the organic phase. Prepare an aqueous solution (using pure water as the solvent) of B.1.351 mRNA from Example 2 as the aqueous phase with pH = 4.

[0172] An organic phase and an aqueous phase were mixed in a 3:1 volume ratio to prepare a lipid nanoparticle suspension on a microfluidic platform (e.g., PNI Ignite). The resulting lipid nanoparticle suspension was then purified and concentrated by centrifugation in a 100 kDa ultrafiltration centrifuge tube, and the concentrated liquid was dispensed.

[0173] The prepared lipid nanoparticles were measured for particle size, PDI, and potential using a laser nanoparticle size analyzer, and the encapsulation efficiency (EE%) was measured using a UV spectrophotometer combined with a RiboGreen RNA kit. Some samples were transfected into CHO cells according to the method in Example 2, and the cell transfection rate was detected by ELISA.

[0174] The physicochemical quality control data of the prepared lipid nanoparticles are shown in the table below:

[0175] Sample Information Particle size (nm) PDI Zeta potential Encapsulation rate mRNA-LNP(II-37) 154.58±27.75 0.1068 22.07 90.5 mRNA-LNP(MC3) 234.08±40.11 0.1259 2.44 40.7

[0176] As can be seen from the table above, the lipid nanoparticles prepared by II-37 have an encapsulation efficiency of up to 90.5%, which is much higher than that of MC3 lipid nanoparticles. Furthermore, the particle size is smaller and more uniform, and the potential is higher.

[0177] The above lipid nanoparticles were transfected into cells, and the results were as follows: Figure 8 As shown, after transfecting cells with mRNA carried by lipid nanoparticles prepared by II-37 (represented by C2 in the figure), the protein expression level in the cells was much higher than that of MC3, indicating that the cell transfection efficiency of lipid nanoparticles prepared by II-37 was very high.

[0178] Example 6: More comprehensive immunogenicity test results

[0179] The mRNA vaccine used is the mRNA-encapsulated LNP lipid particle prepared in Example 3, and the molar ratio of lipid component II-37:DSPC:CHOL:DMG-PEG2000 is 35:15:48.5:1.5.

[0180] BALB / c mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Animal Production License: SCXK (Beijing) 2021-0006), 6-8 weeks old, and female BALB / c mice (SPF grade) were used for the experiment. H11-K18-hACE2 transgenic mice were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. (Production Animal License: SCXK (Jiangsu) 2018-0008), 6 weeks old, SPG grade; this ACE2 humanized mouse model is an ACE2 humanized mouse developed on the C57BL / 6JGpt background mouse, in which the human cytokeratin 18 (Cytokeratin 18, K18) promoter is used to drive the overexpression of hACE2 at the H11 safe harbor locus, for simulating the severe human COVID-19 phenotype. Rhesus monkeys ranged in age from 9 to 22 years old, including both males and females, and were healthy. During the environmental adaptation and quarantine period, no abnormalities were observed in their appearance, mental status, posture, respiration, feces and urine, food intake and drinking water status, which met the experimental requirements.

[0181] Specific IgG binding antibody detection (ELISA method) is mainly used to detect the concentration of total antibodies binding to the immunogen in peripheral blood. The indirect ELISA method is used to detect the content of SARS-CoV-2 specific IgG antibodies in the plasma of immunized animals. 0.05 μg of SARS-CoV-2-B.1.351 Spike antigen protein was coated on a microplate (Thermo, Catalog Number. #442404) and coated overnight at 2-8°C. The plate was blocked with 3% BSA (SIGMA, Catalog Number. #A7030) at room temperature for 1 h, added with diluted mouse plasma (1:50) and monkey plasma (1:500) for incubation for 2 h, and washed 5 times with PBST. Then, HRP-conjugated goat anti-mouse / monkey secondary antibody was added and incubated at room temperature for 30-45 min, followed by 5 washes with PBST. Color development was performed with TMB (Thermofisher, Catalog Number. #34029), incubated at room temperature for 7 min, stop solution (Solarbio, Catalog Number. #C1058) was added to terminate the reaction, and the absorbance was measured at a wavelength of 450 nm to determine the antibody content. Positive antibodies (mouse group: Sino Biological Cat#40591-MM43, rhesus monkey group: ACRO Cat#SPD-M201) were selected, and the polynomial method was used to fit the standard curve to calibrate the total antibody amount.

[0182] The competitive binding assay for the receptor protein angiotensin-converting enzyme 2 (ACE2) (ELISA method) is mainly used to evaluate the ability of antibodies to inhibit the binding of ACE2 to the B.1.351 Spike protein, expressed as "inhibition rate". Using the ELISA Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit (ACRO, Catalog Number #RAS-N031 / RAS-N040 / RAS-N056), mouse / monkey plasma was diluted and added to microplates pre-coated with Human ACE2 Protein. The SARS-CoV-2-B.1.351 neutralizing antibody (Spike RBD) in the plasma specifically competed with the pre-coated Human ACE2 Protein on the microplate for HRP-SARS-CoV-2 Spike. After incubation at 37°C for 1 h, the substrate was added and incubated at 37°C for 20 min for color development, followed by termination with stop solution. The absorbance of the samples was measured at 450 nm / 630 nm using a microplate reader (BioTek, SLXFATS). The OD450 nm reading was subtracted from the OD630 nm reading to reduce background interference. The inhibition rate was calculated as follows: OD450 nm inhibition rate = (1 - sample OD450 nm / Negative Control OD450 nm) × 100%.

[0183] The pseudovirus method (reporter gene method) was used to detect neutralizing antibody levels, assessing the antibody levels that neutralize pseudoviruses containing the B.1.351Spike protein. The degree of antibody invasion into ACE2-overexpressing cell lines was determined by detecting the pseudovirus's ability to infect these cells. Neutralizing antibodies can block the binding of the SARS-CoV-2 pseudovirus's S protein to ACE2, thereby preventing pseudovirus infection of host cells. The degree of viral blockage can be inferred by detecting the expression level of the reporter gene luciferase. Plasma / serum samples from mice / monkeys were collected at different time points before and after vaccine injection. All samples were heat-inactivated at 56°C for 30 min before use. The samples were diluted 20-fold with serum-free DMEM (Gibco Catalog Number #C11995500CP) medium and filtered through a 0.22 μm filter for sterilization. Then, three-fold serial dilutions (6 gradients) were prepared in DMEM medium containing 10% FBS (Gibco Catalog Number #10099-141C). Before use, transfer the SARS-CoV-2-Fluc pseudovirus (Vazyme) from -80℃ to 4℃ or place it on ice to thaw. Dilute the virus to 1-2 × 10⁻⁶ with DMEM medium containing 10% FBS serum.4 TCID50 / ml. Mix the virus suspension with an equal volume of plasma in a 96-well plate and incubate at 37°C for 1 h. Add 50 μL of the solution at a density of 2 × 10⁻⁶ ml to each well. 4 After culturing 293 cells overexpressing ACE2 in cells / wells for 48 h, 100 μL of culture medium was aspirated from the 96-well plate, and 100 μL of Bio-Lite reporter gene (Vazyme, Catalog Number #DD1201) assay reagent was added after equilibration at room temperature. The plate was shaken for 2 min, incubated at room temperature for 5 min, and then the chemiluminescence value (RLU) was detected using a multi-functional microplate reader (TECAN, Spark).

[0184] The level of neutralizing antibodies was detected by the live virus neutralization method, and the ability of antibodies in blood samples to neutralize live viruses was assessed by the live virus infection post-infection cytopathic effect method.

[0185] Immunogenicity assay of mRNA vaccine in BALB / c mice and its results

[0186] The immunization strategy for BALB / c mice is as follows: Figure 9 Two immunizations were administered 21 days apart, and routine blood samples were collected for antibody testing. The experiment included six vaccine dose groups, with a separate PBS control group. The dose ranges for the six groups increased in four-fold increments from the lowest dose of 0.02 μg (0.02, 0.08, 0.3, 1.25, 5) to the highest dose of 20 μg.

[0187] Specific IgG binding antibody detection results as follows Figure 10 As observed, compared with the PBS control group, all dosage groups significantly induced the production of S protein-specific IgG antibodies against strain B.1.351. The median antibody concentration in the highest dose group (20 μg) was 38534 ng / mL, while the median antibody concentrations in the 5 μg and 1.25 μg groups were 13698 and 10987 ng / mL, respectively, showing no statistically significant difference from the 20 μg group. High-titer binding antibodies were also induced in all other groups, and a dose-response relationship was observed among the groups.

[0188] The results of ACE2 competitive binding to the S protein of strain B.1.351 were as follows: Figure 11 The inhibition rate was expressed as the metric. The results showed that the median inhibition rates were 66%, 77%, and 85% for the 0.3 μg, 20 μg, and 20 μg groups, respectively.

[0189] The results of pseudovirus neutralizing antibody levels are as follows: Figure 12 The geometric mean titers (GMT) of the 0.3, 1.25, 5, and 20 μg groups were 211, 183, 149, and 3689, respectively. Starting from the 0.3 μg group, all groups could induce high levels of neutralizing antibodies.

[0190] The results of the S protein analysis of the live virus neutralizing antibody strain B.1.351 are as follows: Figure 13 The GMT values ​​for the 5μg and 20μg groups were 120 and 1280, respectively, consistent with the GMT values ​​observed in the pseudovirus experiment.

[0191] Antibody levels show a dose-dependent effect, and the mRNA vaccine of the present invention can induce dose-dependent specific humoral immunity.

[0192] Subsequently, the inventors conducted multiple immunogenicity evaluations and product stability studies in BALB / c mice. Three batches of pilot-scale samples (with the same composition as LNP in Example 3, and a molar ratio of II-37:DSPC:CHOL:DMG-PEG2000 of 35:15:48.5:1.5) were used for repeated in vitro antigen protein expression level detection and ACE2 competitive inhibition rate experiments. Protein expression was performed in the A549 cell line using the three batches of pilot-scale samples. The CV value of protein expression in the three batches was 9.5%, indicating good uniformity of the obtained Spike protein amount. The antibody levels induced in mice by the three batches of pilot-scale samples were also very consistent. This indicates that the mRNA vaccine of the present invention has good batch-to-batch stability. Furthermore, the inventors stored the mRNA vaccine from the three batches of pilot-scale samples at a low-temperature freezer (-80℃) for 2 days and 2 months, respectively. After thawing according to standard SOP, the samples were infected with A549 cells. Spike protein expression was detected by ELISA after 48 hours. The protein expression was stable, indicating good activity retention after long-term cryopreservation. Results are shown below. Figure 19 .

[0193] Efficacy and challenge test of mRNA vaccine in H11 K18-hACE2 transgenic mice

[0194] The immunization strategy for H11 K18-hACE2 transgenic mice is as follows: Figure 14 Two immunizations were administered 25 days apart. Blood was routinely collected for antibody detection, and mice were transferred to a P3 laboratory for challenge experiments 14 days after the second immunization. Three dose groups were set up, along with a separate saline control group and a blank mouse control group. 0.8 μg, 4 μg, and 20 μg were designated as low, medium, and high dose groups, respectively.

[0195] Specific IgG binding antibody detection, such as Figure 15 As can be seen, compared with the saline challenge control group and the blank control group, all dosage groups significantly induced S protein-specific IgG antibodies against strain B.1.351. The median antibody concentration in the highest dose group (20 μg) was 15679 ng / mL, while the median antibody concentrations in the 4 μg and 0.8 μg groups were 22280 and 8595 ng / mL, respectively, with no statistically significant difference compared to the 20 μg group.

[0196] The results of ACE2 competitive binding to the S protein of strain B.1.351 were as follows: Figure 16 The inhibition rate was used as the metric. The results showed that different dosage groups exhibited varying inhibitory effects due to individual differences.

[0197] Simultaneously, 14 days after the second immunization, the virus was transferred to a P3 laboratory for challenge experiments. The viral titer (B.1.351 strain) was 100 TCID. 50 / 20μl, administered via nasal droplet, was used for challenge. Three days after challenge, mice were sacrificed, and their lungs, brain, heart, spleen, kidneys, and small intestine were collected to detect viral load in the tissues. Results are as follows: Figure 20 As shown, high titers of SARS-CoV-2 were detectable in the lungs and brains of mice receiving the PBS control, while viral titers were significantly reduced in the lungs and brain tissues of mice immunized with different doses of the vaccine.

[0198] Immunogenicity test of mRNA vaccine in rhesus monkeys

[0199] See rhesus monkey immunization strategy. Figure 17 Two immunizations were administered 28 days apart, with routine blood samples collected for antibody detection. Three dose groups were set up in the experiment, along with a separate saline control group. 10, 30, and 100 μg were the low, medium, and high dose groups, respectively.

[0200] The results of ACE2 competitive binding to the S protein of strain B.1.351 were as follows: Figure 18 The inhibition rate was expressed as the metric. The results showed that the median inhibition rates for the 10 μg, 30 μg, and 100 μg dose groups were 52%, 86%, and 94%, respectively.

[0201] The inventors of this invention conducted a correlation analysis on the results of multiple experiments conducted above, and the results proved that both the ACE2 competitive inhibition method and the pseudovirus neutralization method can well characterize the degree of neutralization of live viruses in the corresponding species in mouse and rhesus monkey experiments.

[0202] The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiments. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention. SEQUENCE LISTING <110> Beijing Qichen Biotechnology Co., Ltd. <120> Mutants of the 2019-nCoV S protein and their genetically engineered mRNA and vaccine compositions <130> CPCN21411052a <150> 202111176258.3 <151> 2021-10-09 <160> 9 <170> PatentIn version 3.5 <210> 1 <211> 1273 <212> PRT <213> Unknown <220> <223> 2019-nCoV wild-type S protein <400> 1 Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val 1 5 10 15 Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe 20 25 30 Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val Leu 35 40 45 His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr Trp 50 55 60 Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp 65 70 75 80 Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu 85 90 95 Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser 100 105 110 Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val Ile 115 120 125 Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr 130 135 140 Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val Tyr 145 150 155 160 Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu 165 170 175 Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe 180 185 190 Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr 195 200 205 Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu 210 215 220 Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr 225 230 235 240 Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser 245 250 255 Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro 260 265 270 Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala 275 280 285 Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys 290 295 300 Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val 305 310 315 320 Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys 325 330 335 Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala 340 345 350 Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu 355 360 365 Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro 370 375 380 Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe 385 390 395 400 Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly 405 410 415 Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys 420 425 430 Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn 435 440 445 Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe 450 455 460 Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys 465 470 475 480 Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly 485 490 495 Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val 500 505 510 Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys 515 520 525 Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe Asn 530 535 540 Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe Leu 545 550 555 560 Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala Val 565 570 575 Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe 580 585 590 Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln Val 595 600 605 Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala Ile 610 615 620 His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser 625 630 635 640 Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His Val 645 650 655 Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala 660 665 670 Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg Ser Val Ala 675 680 685 Ser Gln Ser Ile Ile Ala Tyr Thr Met Ser Leu Gly Ala Glu Asn Ser 690 695 700 Val Ala Tyr Ser Asn Asn Ser Ile Ala Ile Pro Thr Asn Phe Thr Ile 705 710 715 720 Ser Val Thr Thr Glu Ile Leu Pro Val Ser Met Thr Lys Thr Ser Val 725 730 735 Asp Cys Thr Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ser Asn Leu 740 745 750 Leu Leu Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Thr 755 760 765 Gly Ile Ala Val Glu Gln Asp Lys Asn Thr Gln Glu Val Phe Ala Gln 770 775 780 Val Lys Gln Ile Tyr Lys Thr Pro Pro Ile Lys Asp Phe Gly Gly Phe 785 790 795 800 Asn Phe Ser Gln Ile Leu Pro Asp Pro Ser Lys Pro Ser Lys Arg Ser 805 810 815 Phe Ile Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly 820 825 830 Phe Ile Lys Gln Tyr Gly Asp Cys Leu Gly Asp Ile Ala Ala Arg Asp 835 840 845 Leu Ile Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu 850 855 860 Leu Thr Asp Glu Met Ile Ala Gln Tyr Thr Ser Ala Leu Leu Ala Gly 865 870 875 880 Thr Ile Thr Ser Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile 885 890 895 Pro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr 900 905 910 Gln Asn Val Leu Tyr Glu Asn Gln Lys Leu Ile Ala Asn Gln Phe Asn 915 920 925 Ser Ala Ile Gly Lys Ile Gln Asp Ser Leu Ser Ser Thr Ala Ser Ala 930 935 940 Leu Gly Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn 945 950 955 960 Thr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val 965 970 975 Leu Asn Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln 980 985 990 Ile Asp Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val 995 1000 1005 Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn 1010 1015 1020 Leu Ala Ala Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys 1025 1030 1035 Arg Val Asp Phe Cys Gly Lys Gly Tyr His Leu Met Ser Phe Pro 1040 1045 1050 Gln Ser Ala Pro His Gly Val Val Phe Leu His Val Thr Tyr Val 1055 1060 1065 Pro Ala Gln Glu Lys Asn Phe Thr Thr Ala Pro Ala Ile Cys His 1070 1075 1080 Asp Gly Lys Ala His Phe Pro Arg Glu Gly Val Phe Val Ser Asn 1085 1090 1095 Gly Thr His Trp Phe Val Thr Gln Arg Asn Phe Tyr Glu Pro Gln 1100 1105 1110 Ile Ile Thr Thr Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val 1115 1120 1125 Val Ile Gly Ile Val Asn Asn Thr Val Tyr Asp Pro Leu Gln Pro 1130 1135 1140 Glu Leu Asp Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn 1145 1150 1155 His Thr Ser Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn 1160 1165 1170 Ala Ser Val Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu 1175 1180 1185 Val Ala Lys Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu 1190 1195 1200 Gly Lys Tyr Glu Gln Tyr Ile Lys Trp Pro Trp Tyr Ile Trp Leu 1205 1210 1215 Gly Phe Ile Ala Gly Leu Ile Ala Ile Val Met Val Thr Ile Met 1220 1225 1230 Leu Cys Cys Met Thr Ser Cys Cys Ser Cys Leu Lys Gly Cys Cys 1235 1240 1245 Ser Cys Gly Ser Cys Cys Lys Phe Asp Glu Asp Asp Ser Glu Pro 1250 1255 1260 Val Leu Lys Gly Val Lys Leu His Tyr Thr 1265 1270 <210> 2 <211> 1205 <212> PRT <213> Artificial Sequence <220> <223> 2019-nCoV S protein mutant <400> 2 Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val 1 5 10 15 Asn Phe Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe 20 25 30 Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val Leu 35 40 45 His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr Trp 50 55 60 Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe Ala 65 70 75 80 Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu 85 90 95 Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser 100 105 110 Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val Ile 115 120 125 Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr 130 135 140 Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val Tyr 145 150 155 160 Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu 165 170 175 Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe 180 185 190 Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr 195 200 205 Pro Ile Asn Leu Val Arg Gly Leu Pro Gln Gly Phe Ser Ala Leu Glu 210 215 220 Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr 225 230 235 240 Leu His Ile Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser Gly Trp Thr 245 250 255 Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro Arg Thr Phe 260 265 270 Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala Val Asp Cys 275 280 285 Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys Ser Phe Thr 290 295 300 Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val Gln Pro Thr 305 310 315 320 Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly 325 330 335 Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg 340 345 350 Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser 355 360 365 Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu 370 375 380 Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg 385 390 395 400 Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly Asn Ile Ala 405 410 415 Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala 420 425 430 Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr 435 440 445 Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp 450 455 460 Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val 465 470 475 480 Lys Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro 485 490 495 Thr Tyr Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe 500 505 510 Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr 515 520 525 Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe Asn Gly Leu Thr 530 535 540 Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe Leu Pro Phe Gln 545 550 555 560 Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala Val Arg Asp Pro 565 570 575 Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe Gly Gly Val 580 585 590 Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln Val Ala Val Leu 595 600 605 Tyr Gln Gly Val Asn Cys Thr Glu Val Pro Val Ala Ile His Ala Asp 610 615 620 Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser Asn Val Phe 625 630 635 640 Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His Val Asn Asn Ser 645 650 655 Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala Ser Tyr Gln 660 665 670 Thr Gln Thr Asn Ser Pro Gly Ser Ala Ser Ser Val Ala Ser Gln Ser 675 680 685 Ile Ile Ala Tyr Thr Met Ser Leu Gly Val Glu Asn Ser Val Ala Tyr 690 695 700 Ser Asn Asn Ser Ile Ala Ile Pro Thr Asn Phe Thr Ile Ser Val Thr 705 710 715 720 Thr Glu Ile Leu Pro Val Ser Met Thr Lys Thr Ser Val Asp Cys Thr 725 730 735 Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ser Asn Leu Leu Leu Gln 740 745 750 Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Thr Gly Ile Ala 755 760 765 Val Glu Gln Asp Lys Asn Thr Gln Glu Val Phe Ala Gln Val Lys Gln 770 775 780 Ile Tyr Lys Thr Pro Pro Ile Lys Asp Phe Gly Gly Phe Asn Phe Ser 785 790 795 800 Gln Ile Leu Pro Asp Pro Ser Lys Pro Ser Lys Arg Ser Pro Ile Glu 805 810 815 Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly Phe Ile Lys 820 825 830 Gln Tyr Gly Asp Cys Leu Gly Asp Ile Ala Ala Arg Asp Leu Ile Cys 835 840 845 Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu Leu Thr Asp 850 855 860 Glu Met Ile Ala Gln Tyr Thr Ser Ala Leu Leu Ala Gly Thr Ile Thr 865 870 875 880 Ser Gly Trp Thr Phe Gly Ala Gly Pro Ala Leu Gln Ile Pro Phe Pro 885 890 895 Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn Val 900 905 910 Leu Tyr Glu Asn Gln Lys Leu Ile Ala Asn Gln Phe Asn Ser Ala Ile 915 920 925 Gly Lys Ile Gln Asp Ser Leu Ser Ser Thr Pro Ser Ala Leu Gly Lys 930 935 940 Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu Val 945 950 955 960 Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val Leu Asn Asp 965 970 975 Ile Leu Ser Arg Leu Asp Pro Pro Glu Ala Glu Val Gln Ile Asp Arg 980 985 990 Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln Gln 995 1000 1005 Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn Leu Ala Ala 1010 1015 1020 Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys Arg Val Asp 1025 1030 1035 Phe Cys Gly Lys Gly Tyr His Leu Met Ser Phe Pro Gln Ser Ala 1040 1045 1050 Pro His Gly Val Val Phe Leu His Val Thr Tyr Val Pro Ala Gln 1055 1060 1065 Glu Lys Asn Phe Thr Thr Ala Pro Ala Ile Cys His Asp Gly Lys 1070 1075 1080 Ala His Phe Pro Arg Glu Gly Val Phe Val Ser Asn Gly Thr His 1085 1090 1095 Trp Phe Val Thr Gln Arg Asn Phe Tyr Glu Pro Gln Ile Ile Thr 1100 1105 1110 Thr Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val Val Ile Gly 1115 1120 1125 Ile Val Asn Asn Thr Val Tyr Asp Pro Leu Gln Pro Glu Leu Asp 1130 1135 1140 Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn His Thr Ser 1145 1150 1155 Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala Ser Val 1160 1165 1170 Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu Val Ala Lys 1175 1180 1185 Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr 1190 1195 1200 Glu Gln 1205 <210> 3 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Domains that assist in the formation of trimers <400> 3 Gly Tyr Ile Pro Glu Ala Pro Arg Asp Gly Gln Ala Tyr Val Arg Lys 1 5 10 15 Asp Gly Glu Trp Val Leu Leu Ser Thr Phe Leu Gly 20 25 <210> 4 <211> 3615 <212> DNA <213> Artificial Sequence <220> <223> Artificial sequence <400> 4 atgttcgtgt tcctggtgct gcttcccctg gtctctagcc agtgcgtgaa cttcacgacc 60 cggacccaac tgccccccgc gtacacaaac tccttcacca gaggcgtgta ctaccctgac 120 aaggtgttcc gcagcagcgt gctgcacagc acccaggacc tgttcctccc attcttcagc 180 aacgtgacct ggttccacgc catccacgtg tccggcacca atggaacaaa gagatttgcg 240 aaccccgtgc tacctttcaa cgacggcgtg tacttcgcct ccaccgagaa gagcaacatc 300 atccggggct ggatcttcgg caccaccctg gactctaaaa cccagagcct gctgatcgtg 360 aataatgcca ccaacgtggt gatcaaggtg tgcgagttcc agttctgcaa cgaccctttc 420 ctgggcgtct actaccacaa gaacaacaag agttggatgg aaagcgagtt cagagtgtac 480 tcttctgcta acaactgcac cttcgagtac gtgtcccagc ctttcctgat ggacctggaa 540 ggcaagcagg ggaacttcaa gaacctgcgg gagttcgtgt tcaagaacat cgacgggtat 600 ttcaagatct actccaagca cacacctatc aatctggtga gaggcctgcc ccagggcttc 660 agcgccctgg aacctctggt cgacctgcca atcggcatca acatcacccg gttccaaaca 720 ctgcatatca gctacctgac acctggcgat agctcctccg gctggaccgc cggcgctgcc 780 gcttattacg tcggctacct gcagcctaga acgttcctgc tgaagtacaa cgagaacggc 840 accatcaccg acgccgtcga ctgccccctg gaccccctct ccgagacaaa atgcaccctg 900 aagagcttca ctgttgaaaa gggcatctac cagaccagca actttagagt gcagcctaca 960 gagtctatcg tgagattccc taacattacc aacctgtgtc cttttggaga agtgttcaac 1020 gccacaagat tcgcttctgt gtatgcctgg aaccggaaga gaatctcgaa ctgcgtggct 1080 gattacagcg tgctgtacaa cagcgctagc tttagcacat ttaagtgcta cggcgtgagc 1140 cccaccaagc tgaatgattt gtgcttcaca aatgtgtacg ccgactcttt cgtgataaga 1200 ggggacgagg tgcggcagat agctccaggc cagaccggca acatcgccga ttacaattac 1260 aagctgcctg acgactttac cggatgtgtg atcgcctgga acagcaacaa cctggatagc 1320 aaggtgggcg gaaactacaa ctacctgtac agactgttcc ggaaatctaa ccttaagcct 1380 tttgagcggg atatcagcac cgagatctac caagctggct ctacaccctg caacggcgtg 1440 aaggggttta attgttactt ccccctgcag agctacggct tccaaccgac ctacggagtg 1500 ggctaccagc cctaccgggt cgtggtgctg agctttgagc tgctgcacgc ccctgctaca 1560 gtgtgcggcc ccaagaagtc tacgaacctg gtgaagaaca agtgtgtgaa ttttaatttc 1620 aacggactga ccggcacagg cgtcctgacc gaatctaaca agaaattcct ccctttccag 1680 cagttcggga gagatatcgc cgacaccacc gacgccgtgc gggaccctca aacactggaa 1740 atcctggata tcaccccttg ttctttcgga ggcgtgtccg tgatcacccc aggtacgaac 1800 acatctaacc aggtggctgt gctgtaccag ggcgtgaact gcaccgaggt gcctgtggcc 1860 attcacgccg accagctgac tcctacctgg cgggtgtaca gcacgggctc caacgtgttt 1920 cagaccagag ctggctgtct gatcggagcc gagcacgtga acaactctta tgagtgcgat 1980 atccccatcg gcgctggaat ctgtgcctcc taccagactc aaaccaacag ccctggcagc 2040 gctagcagcg tggccagcca gagcatcatc gcctacacca tgagcctggg agtcgaaaac 2100 agcgtggcct actcaaacaa ctccatcgct atccctacca acttcaccat cagcgtaacg 2160 accgaaatcc tgcccgtgag catgaccaag accagcgtgg actgcacaat gtacatctgc 2220 ggcgatagca cagaatgcag caatctgcta ctgcagtacg gtagcttttg cacccaactg 2280 aatagagccc tgaccggcat cgccgtggaa caggataaaa acacccaaga ggtcttcgct 2340 caggtgaagc agatctacaa gacacctccc atcaaggact tcggaggatt caactttagc 2400 cagatcctgc ctgatccaag caaacctagc aagcggagtc ctatcgagga cctgctgttt 2460 aacaaggtga cactggccga cgccggcttc atcaagcagt atggcgactg tctgggcgac 2520 atcgccgcca gggatctgat ctgtgcccaa aaattcaacg gcctgacagt gctgccacct 2580 ctgctgaccg acgagatgat cgctcaatac accagcgccc tcctcgccgg cacgatcacc 2640 agcggctgga cattcggcgc cggccctgcc ctccagatcc ctttccctat gcagatggcc 2700 tacagattca acggcatcgg cgtgacacaa aacgtgctgt acgaaaacca gaagctgatc 2760 gccaatcagt ttaatagcgc catcgggaag atccaggata gcctgtcatc taccccttct 2820 gccctgggaa agctgcagga cgtggtgaac cagaacgccc aggccctgaa caccctggtg 2880 aaacagctgt ctagcaactt cggcgctatc agcagcgtgc tgaatgatat cctgagcaga 2940 ctggatcctc ctgaggccga ggtgcagatc gacagattga tcaccggccg gctgcagagc 3000 ctgcaaacct acgttacaca gcagctgatc agagccgctg aaatcagagc ctctgccaac 3060 ctggccgcca ccaaaatgag cgagtgcgtg ctgggacaga gcaaaagggt ggacttctgc 3120 gggaagggct accacctcat gagttttccc cagagcgccc cccacggcgt ggtgttcctg 3180 cacgtgacat atgtcccggc ccaggagaaa aactttacaa cagcccctgc catttgccat 3240 gacggaaagg cccacttccc tcgggaaggt gtgttcgtga gcaacggcac acactggttc 3300 gtgacccaga gaaacttcta cgagcctcaa atcatcacca cagacaacac cttcgttagt 3360 ggaaattgcg acgtggttat cggcatcgtg aacaacaccg tctacgaccc actgcagcct 3420 gaactggata gcttcaagga ggaactggat aagtatttca agaaccacac ctcccccgac 3480 gtggatctgg gcgacattag cggcatcaac gccagcgtgg tgaacatcca gaaagagatc 3540 gatagactta atgaggtggc caagaacctg aacgagagcc tgatcgacct gcaggagctc 3600 ggcaaatacg agcag 3615 <210> 5 <211> 84 <212> DNA <213> Artificial Sequence <220> <223> Artificial sequence <400> 5 ggctatatcc cagaggcccc tagagatggc caggcctacg ttagaaagga cggcgagtgg 60 gtcctgctga gcacattcct gggc 84 <210> 6 <211> 50 <212> RNA <213> Artificial Sequence <220> <223> Artificial sequence <400> 6 acauuugcuu cugacacaac uguguucacu agcaaccuca aacagacacc 50 <210> 7 <211> 88 <212> RNA <213> Artificial Sequence <220> <223> Artificial sequence <400> 7 gcuggagccu cgguagccgu uccuccugcc cgcugggccu cccaacgggc ccuccucccc 60 uccuugcacc ggcccuuccu ggucuuug 88 <210> 8 <211> 3702 <212> RNA <213> Artificial Sequence <220> <223> Artificial sequence <400> 8 auguucgugu uccuggugcu gcuuccccug gucucuagcc augugcgugaa cuucacgacc 120. cggacccaac ugccccccgc guacacaaac uccuucacca gaggcgugua cuacccugac aagguguucc gcagcagcgu gcugcacagc acccaggacc uguuccuccc auucuucagc 240. aacgugaccu gguuccacgc cauccacgug uccggcacca auggacaaa gagauuugcg aaccccgugc uaccuuucaa cgacggcgug uacuucgccu ccaccgagaa gagcaacauc auccggggcu ggaucuucgg caccacccug gacucuaaaa cccagagccu gcugaucgug aauaaugcca ccaacguggu gaucaaggug ugcgaguucc aguucugca cgacccuuuc cuggcgucu acuaccacaa covered aaagcgaguu cagaguguac 540. 540. 540. 540. 540. 540. 540. 540. 540. 540. 540 ggcaagcagg ggacuucaa ggaccugcgg gaguucgugu ucaagaacau cgacggguau 660. uucaagaucu acuccaagca cacaccuauc aaucugguga gaggccugcc ccagggcuuc agcgcccugg aaccucugg cgaccugcca aucggcauca acaucacccg 720. s.s.s.s.s.s.s.s.s.s.s.s.s.s.s.s.s.s.s cugcauauca gcuaccugac accuggcgau agcuccuccg gcugaccgc cggcgcugcc 780 840 accaucaccg acgccgucga cugcgccccug gacccccucu ccgagacaaa augcacccug 900 aagagcuuca cuguugaaaa gggcaucuac cagaccagca acuuuagagu gcagccuaca 960 1020 gccacaagau ucgcuucugu guaugccugg aaccgggaaga gauucucgaa cugcguggcu 1080 gauuacagcg ugcuguacaa cagcgcuagc uuuagcacau uuaagugcua cggcgugagc 1140 cccaccaagc ugaaugauuu gugcuucaca aauguguacg ccgacucuuu cgugauaaga 1200 ggggacgagg ugcggcagau agcuccaggc cagaccggca acaucgccga uuacaauuac 1260 aagcugccug acgacuuuac cggaugugug aucgccugga acagcaacaa ccuggauagc 1320 aaggugggcg gaacuaacaa cuaccuguac agacuguucc ggaaaucuaa ccuuaagccu 1380 1440 aagggguua auuguuacuu cccccugcag agcuacggcu uccaaccgac cuacggagug 1500 ggcuaccagc ccuaccgggu cguggugcug agcuuugagc ugcugcacgc cccugcuaca 1560 gugugcggcc ccaagaaguc uacgaaccug gugaagaaca agugugugaa uuuaauuuc 1620 aacggacuga ccggcacagg cguccugacc gaaucuaaca agaaauuccu cccuuuccag 1680 caguucggga gagauaucgc cgacaccacc gacgccgugc gggacccuca aacacuggaa 1740 auccuggaua ucacccccuug uucuuucgga ggcguguccg ugaucacccc agguacgaac 1800 acaucuaacc agguggcugu gcuguaccag ggcgugaacu gcaccgaggu gccuguggcc 1860 1920 1980 auccccaucg gcgcuggau cgugcccucc uaccagacuc aaccaacag cccuggcagc 2040 gcuagcagcg uggccagcca gagcaucauc gccuacacca ugagccugggg agucgaaaac 2100 2160 accgaaaucc ugcccgugag caugaccaag accagcgugg acugcacaau guacaucugc 2220 ggcgauagca cagaaugcag caaucugcua cugcaguacg guagcuuuug cacccaacug 2280 aauagagccc ugaccggcau cgccguggaa caggauaaaa acacccaaga ggucuucgcu 2340 caggugaagc agaucuacaa gacaccuccc aucaaggacu ucggaggauu caacuuuagc 2400 cagauccugc cugauccaag caaaccuagc aagcggaguc cuaucgagga ccugcuguuu 2460 aacaagguga cacuggccga cgccggcuuc aucaagcagu auggcgacug ucugggcgac 2520 aucgccgcca gggaucugau cugugcccaa aaauucaacg gccugacagu gcugccaccu 2580 cugcugaccg acgagaugau cgcucaauac accagcgccc uccucgccgg cacgaucacc 2640 agcggcugga cauucggcgc cggcccugcc cuccagaucc cuuucccuau gcagauggcc 2700 uacagauuca acggcaucgg cgugacacaa aacgugcugu acgaaaacca gaagcugauc 2760 gccaaucagu uuaauagcgc caucgggaag auccaggaua gccugucauc uaccccuucu 2820 gcccugggaa agcugcagga cguggugaac cagaacgccc aggcccugaa cacccuggug 2880 2940 3000 3060 cuggccgcca caaaaugag cgagugcgug cugggacaga gcaaaagggu ggacuucugc 3120 gggaagggcu accaccucau gaguuuuccc cagagcgccc cccacggcgu gguguuccug 3180 cacgugacau augucccggc ccaggagaaa acuuuacaa cagccccugc cauuugccau 3240 gacggaaagg cccacuuccc ucgggaaggu guguucguga gcaacggcac acacugguuc 3300 gugacccaga gaacuucua cgagccucaa aucaucacca cagacaacac cuucguuagu 3360 ggaaauugcg acgugguuau cggcaucgug aacaacaccg ucuacgaccc acugcagccu 3420 gaacuggaua gcuucaaagga ggaacuggau aaguauuuca agaaccacac cucccccgac 3480 guggauucugg gcgacauuag cggcaucaac gccagcgugg ugaacaucca gaagagauc 3540 gauagacuua augagguggc caagaaccug aacgagagcc ugaucgaccu gcaggagcuc 3600 ggcaaauacg agcagggcua uaucccagag gccccuagag auggccaggc cuacguuaga 3660 aaggacggcg aguggguccu gcugagcaca uuccugggcu ga 3702 <210> 9 <211> 4093 <212> RNA <213> Artificial Sequence <220> <223> Artificial Sequence <400> 9 gggagaccgg ccucgagaca uuugcuucug acacaacugu guucacuagc aaccucaaac 60 agacaccaag cuugccacca uguucguguu ccuggugcug cuuccccugg ucucuagcca 120 gugcgugaac uucacgaccc ggacccaacu gccccccgcg uacacaaacu ccuucaccag 180 aggcguguac uacccugaca agguguuccg cagcagcgug cugcacagca cccaggaccu 240 guuccuccca uucuucagca acgugaccug guuccacgcc auccacgugu ccggcaccaa 300 uggaacaaag agauuugcga accccgugcu accuuucaac gacggcgugu acuucgccuc 360 caccgagaag agcaacauca uccggggcug gaucuucggc accacccugg acucuaaaac 420 ccagagccug cugaucguga auaaugccac caacguggug aucaaggugu gcgaguucca 480 guucugcaac gacccuuucc ugggcgucua cuaccacaag aacaacaaga guuggaugga 540 600 uuuccugaug gacuggaag ccaagcaggg gaacuucaag aaccugcggg aguucguuu 660 caagaacauc gacggguauu ucaagaucua cuccaagcac acaccuauca aucuggugag 720 aggccugccc cagggcuuca gcgcccugga accucugguc gccugccaa ucggcaucaa 780 caucacccgg uuccaaacac ugcauaucag cuaccugaca ccuggcgaua gcuccucccgg 840 cuggaccgcc ggcgcugccg cuuauuacgu cggcuaccug cagccuagaa cguuccugcu 900 960 cgagacaaaa ugcacccuga agagcuucac uguugaaaag ggcaucuacc agaccagcaa 1020 1080 uuuggagaa guguucaacg ccacaagauu cgcuucugug uaugccugga accggagaag 1140 aaucucgaac ugcguggcug auuacagcgu gcuguacaac agcgcuagcu uaagcacauu 1200 uaagugcuac ggcgugagcc ccaccaagcu gaaugauuug ugcuucacaa auguguacgc 1260 cgacuuuuc gugauaagag gggacgaggu gcggcagaua gcuccaggcc agaccggcaa 1320 caucgccgau uacaauuaca agcugccuga cgacuuuacc ggauguguga ucgccuggaa 1380 cagcaacaac cuggauagca aggugggcgg aaacuacaac uaccuguaca gacuguuccg 1440 gaaaucuaac cuuaagccuu uugagcggga uaucagcacc gagaucuacc aagcuggcuc 1500 uacaccguc aacggcguga agggguuuaa uuguuacuuc ccccugcaga gcuacggcuu 1560 ccaaccgacc uacggagugg gcuaccagcc cuaccggguc guggugcuga gcuuugagcu 1620 gcugcacgcc ccugcuacag uggcggccc caagaagucu acgaaccugg ugaagaacaa 1680 gugugugaau uuuauauuca acggacugac cggcacaggc guccugaccg aaucuaacaa 1740 gaaauuccuc ccuuuccagc aguucgggag agauaucgcc gacaccaccg acgccgugcg 1800 ggacccucaa acacuggaaaa uccuggauau caccccuugu ucuuucggag gcguguccgu 1860 gaucacccca gguacgaaca caucuaacca gguggcugug cuguaccagg gcgugaacug 1920 1980 cacgggcucc aacguguuuc agaccagagc uggcugucug aucggagccg agcacgugaa 2040 caacucuuau gagugcgaua uccccaucgg cgcuggaauc uguggccuccu accagacuca 2100 aaccaacagc ccuggcagcg guagcagcgu ggccagccag agcaucaucg ccuacaccau 2160 gagccuggga gucgaaaaca gcguggccua cuaacaac uccaucgcua ucccuaccaa 2220 cuucaccauc agcguaacga ccgaaauccu gcccgugagc augaccaaga ccagcgugga 2280 2340 uagcuuuugc acccaacuga auagagcccu gaccggcauc gccguggaac aggauaaaaa 2400 cacccaagag gucuucgcuc aggugaagca gaucuacaag acaccuccca ucaaggacuu 2460 cggaggauuc aacuuuagcc agauccugcc ugauccaagc aaaccuagca agcggagucc 2520 uaucgaggac cugcuguuua acaaggugac acuggccgac gccggcuuca ucaagcagua 2580 uggcgacugu cugggcgaca ucgccgccag ggaucugauc ugugcccaaa aauucaacgg 2640 2700 ccucgccggc acgaucacca gcggcuggac auucggcgcc ggcccugccc uccagauccc 2760 uuucccuaug cagauggccu acagauucaa cggcaucgg gugacacaaa acgugcugua 2820 cgaaaaccag aagcugaucg ccaaucaguu uaauagcgcc aucgggaaga uccaggauag 2880 ccugucaucu acccccuucug cccugggaaa gcugcaggac guggugaacc agaacgccca 2940 ggcccugaac acccugguga aacagcugc uagcaacuuc ggcgcuauca gcagcgugcu 3000 gaaugauauc cugagcagac uggauccucc ugaggccgag gugcagaucg acagauugau 3060 3120 aaucagagcc ucugccaacc uggccgccac caaaaugagc gagugcgugc uggcagag 3180 caaaagggug gacuucugcg ggaagggcua ccaccucaug aguuucccc agagcgcccc 3240 ccacggggug guguucgc acgugacaua ugucccggcc caggagaaaa acuuuacaac 3300 agccccugcc auuugccaug acggaaaggc ccacuuccu cgggaaggug uguucgugag 3360 caacggcaca cacugguucg ugacccagag aaacuucuac gagccucaaa ucaucaccac 3420 agacaacacc uucguuagug gaaauugcga cgugguuauc ggcaucguga acaacaccgu 3480 cuacgaccca cugcagccug aacuggauag cuucaaggag gaacuggaua aguauuucaa 3540 gaaccacacc ucccccgacg uggaucuggg cgacauuagc ggcaucaacg ccagcguggu 3600 gaacauccag aaagagaucg auagacuuaa ugagguggcc aagaaccuga acgagagccu 3660 gaucgaccug caggagcucg gcaaauacga gcagggcuau aucccagagg ccccuagaga 3720 uggccaggcc uacguuagaa aggacggcga guggguccug cugagcacau uccugggcug 3780 agaauucgcu ggagccucgg uagccguucc uccugcccgc ugggccuccc aacgggcccu 3840 ccuccccucc uugcaccggc ccuuccuggu cuuuggcugg agccucggua gccguuccuc 3900 cugcccgcug ggccucccaa cgggcccucc uccccuccuu gcaccggccc uuccuggucu 3960 uuguuaauua aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4020 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4080 aaaaaaaaac uag 4093

Claims

1. A mutant of the S protein of 2019-nCoV, characterized in that, It consists of an amino acid sequence as shown in SEQ ID NO:2 and an amino acid sequence as shown in SEQ ID NO:3, which are directly linked from the N-terminus to the C-terminus.

2. A DNA molecule, characterized in that, The DNA molecule encodes the S protein mutant of 2019-nCoV as described in claim 1.

3. The DNA molecule as described in claim 2, characterized in that, The nucleotide sequence of the DNA molecule consists of the nucleotide sequences shown in SEQ ID NO:4 and SEQ ID NO:5, which are directly linked from the 5' end to the 3' end.

4. An expression carrier, characterized in that, It comprises the DNA molecule as described in claim 2 or 3.

5. A cell, characterized in that, It comprises the DNA molecule of claim 2 or 3 or the expression vector of claim 4.

6. An mRNA molecule, characterized in that, An open reading frame containing an S protein mutant of 2019-nCoV as described in claim 1.

7. The mRNA molecule as described in claim 6, characterized in that, The nucleotide sequence of the open reading frame is shown in SEQ ID NO:

8.

8. The mRNA molecule as described in claim 6 or 7, characterized in that, The mRNA contains a 5' UTR, an open reading frame encoding the S protein mutant of 2019-nCoV, a 3' UTR, and a poly-A tail from the 5' end to the 3' end.

9. The mRNA molecule as described in claim 8, characterized in that, The 5'UTR contains the nucleotide sequence shown in SEQ ID NO:

6.

10. The mRNA molecule as described in claim 8, characterized in that, The 3'UTR contains two nucleotide sequences connected end-to-end as shown in SEQ ID NO:

7.

11. The mRNA molecule as described in claim 8, characterized in that, The poly-A tail is 100-150 nucleotides in length.

12. The mRNA molecule as described in claim 8, characterized in that, The mRNA further contains a Kozak sequence, which is GCCACC.

13. The mRNA molecule as described in claim 8, characterized in that, The mRNA further includes a 5' cap, which is CAP1.

14. The mRNA molecule as described in claim 6, characterized in that, It contains the nucleotide sequence shown in SEQ ID NO:

9.

15. A nucleic acid molecule, characterized in that, It encodes the mRNA molecule as described in any one of claims 6-14.

16. An in vitro transcription vector, characterized in that, It comprises nucleotide sequences encoding a 5'UTR, a 3'UTR, and a poly-A tail that are operatively linked; the 5'UTR comprises the nucleotide sequence shown in SEQ ID NO:6; the 3'UTR comprises two end-to-end nucleotide sequences shown in SEQ ID NO:7; and the poly-A tail is 50-200 nucleotides in length. The in vitro transcription vector further comprises the nucleotide sequence of the ORF encoding the 2019-nCoV S protein mutant, the nucleotide sequence of the 2019-nCoV S protein mutant ORF being shown in SEQ ID NO:

8.

17. A vaccine composition, characterized in that, It comprises the S protein mutant of 2019-nCoV as described in claim 1, or the mRNA molecule as described in any one of claims 6-14.

18. The vaccine composition of claim 17, characterized in that, The vaccine composition also contains pharmaceutically acceptable excipients and / or adjuvants.

19. The vaccine composition of claim 17 or 18, further comprising lipid nanoparticles, wherein mRNA is located in the lipid nanoparticles, and the lipid nanoparticles contain 30-60 mol% of ionizable cationic lipid molecules of formula C, 5-30 mol% of neutral lipid molecules, 30-50 mol% of cholesterol lipid molecules, and 0.4-10 mol% of PEGylated lipid molecules, comprising 30-60 mol% of the total lipid molecules. Formula C Each n3 is independent of each other, either the same or different, and each n3 is selected from integers from 1 to 8; each m3 is independent of each other, either the same or different, and each m3 is selected from integers from 0 to 8. Neutral lipid molecules are selected from phosphatidylcholine compounds represented by formula E. E, Phosphatidylethanolamine compounds represented by formula F F, wherein Ra, Rb, Rc, and Rd are independently selected from straight-chain or branched C10-30 alkyl groups and straight-chain or branched C10-30 alkenyl groups; Cholesterol lipid molecules are selected from cholesterol, 5-heptadecylresorcinol and cholesterol hemisuccinate; PEGylated lipid molecules comprise a lipid moiety and a PEG-based polymer moiety, denoted as "lipid moiety-PEG-number-average molecular weight". The lipid moiety is selected from dilauroyl glycerol, dimyristoyl glycerol, dipalmitoyl glycerol, distearyl glycerol, dilauryl glyceramide, dimyristoyl glyceramide, dipalmitoyl glyceramide, distearyl glyceramide, 1,2-distearyl-sn-glycerol-3-phosphate ethanolamine, and 1,2-dimyristoyl-sn-glycerol-3-phosphate ethanolamine. The number-average molecular weight of PEG is 130 to 50,000.

20. The vaccine composition of claim 19, characterized in that, It contains 32-55 mol% of ionizable cationic lipid molecules of formula C, 8-20 mol% of neutral lipid molecules, 35-50 mol% of cholesterol lipid molecules, and 0.5-5 mol% of PEGylated lipid molecules.

21. The vaccine composition according to claim 20, characterized in that, It contains 34-46 mol% of ionizable cationic lipid molecules of formula C, 9-16 mol% of neutral lipid molecules, 37-49 mol% of cholesterol lipid molecules, and 1.3-2.7 mol% of PEGylated lipid molecules.

22. The vaccine composition of claim 19, characterized in that, Each n3 is selected from integers from 4 to 8, and each m3 is selected from integers from 4 to 8.

23. The vaccine composition according to claim 22, characterized in that, Each n3 is identical to the others, and each m3 is identical to the others.

24. The vaccine composition according to claim 23, characterized in that, Equation C is .

25. The vaccine composition according to claim 19, characterized in that, Ra, Rb, Rc, and Rd are each selected independently from CH3(CH2). 17 CH2-, CH3(CH2) 15 CH2-, CH3(CH2) 13 CH2-, CH3(CH2) 11 CH2-, CH3(CH2)9CH2-, CH3(CH2)7CH2-, CH3(CH2)7-CH=CH-(CH2)7-, CH3(CH2)4CH=CHCH2CH=CH(CH2)7-, CH3(CH2)7-CH=CH-(CH2)9-.

26. The vaccine composition of claim 19, characterized in that, The number average molecular weight of PEG is 150 to 30,000.

27. The vaccine composition according to claim 26, characterized in that, The number average molecular weight of PEG is 150 to 10,000.

28. The vaccine composition according to claim 27, characterized in that, The number average molecular weight of PEG is 300 to 3,000.

29. The vaccine composition according to claim 28, characterized in that, The number average molecular weight of PEG is 1,500 to 2,500.

30. The vaccine composition according to claim 19, characterized in that, The total mass ratio of lipid molecules to mRNA is 5-20:1.

Citation Information

Patent Citations

  • Lipid nanoparticle composition and drug delivery system prepared from same

    CN115957187A